var title_f2_16_2304="Algorithm for overlap disorders";
var content_f2_16_2304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An algorithm for diagnosis and management of systemic rheumatic diseases and overlap syndromes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 529px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCTD: mixed connective tissue disease; Rhupus: overlap of rheumatoid arthritis and systemic lupus erythematosus (SLE).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2304=[""].join("\n");
var outline_f2_16_2304=null;
var title_f2_16_2305="Neonatal body stalk anomaly 2";
var content_f2_16_2305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Notice the severe scoliosis and chest wall deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO and A Hilton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2305=[""].join("\n");
var outline_f2_16_2305=null;
var title_f2_16_2306="Insomnia";
var content_f2_16_2306=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Insomnia (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/16/2306/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2306/contributors\" id=\"au1847\">",
"       Michael H Bonnet, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2306/contributors\" id=\"au1875\">",
"       Donna L Arand, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/16/2306/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2306/contributors\" id=\"se8034\">",
"       Ruth Benca, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/16/2306/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2306/contributors\" id=\"de8764\">",
"       April F Eichler, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/16/2306?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Insomnia is defined as difficulty falling asleep, difficulty staying asleep, or unrefreshing sleep. In general, people with insomnia sleep less or sleep poorly despite having an adequate chance to sleep. The poor sleep may lead to trouble functioning during the daytime.",
"    </p>",
"    <p>",
"     Insomnia is not defined by the number of hours slept because \"sufficient sleep\" can vary from one person to another. Sleep requirements may also decrease with age.",
"    </p>",
"    <p>",
"     Insomnia is the most common sleep complaint in the United States. While almost everyone has an occasional night of poor sleep, approximately 10 percent of adults have long-term or chronic insomnia.",
"    </p>",
"    <p>",
"     This article will review the symptoms, causes, and diagnosis of insomnia. Treatment of insomnia is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"      \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about insomnia is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"      \"Overview of insomnia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INSOMNIA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Common symptoms of insomnia include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty falling asleep or staying asleep",
"      </li>",
"      <li>",
"       Variable sleep, such as several nights of poor sleep followed by a night of better sleep.",
"      </li>",
"      <li>",
"       Daytime fatigue or sleepiness",
"      </li>",
"      <li>",
"       Forgetfulness",
"      </li>",
"      <li>",
"       Poor concentration",
"      </li>",
"      <li>",
"       Irritability",
"      </li>",
"      <li>",
"       Anxiety",
"      </li>",
"      <li>",
"       Depression",
"      </li>",
"      <li>",
"       Reduced motivation or energy",
"      </li>",
"      <li>",
"       Increased errors or accidents",
"      </li>",
"      <li>",
"       Ongoing worry about sleep",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For many people, the symptoms of insomnia interfere with personal relationships, job performance, and daily function. In one survey, people who experienced chronic insomnia had a two-fold increased risk of automobile accidents compared with people who were fatigued for other reasons [",
"     <a class=\"abstract\" href=\"UTD.htm?2/16/2306/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     People with insomnia have an impaired sense of sleep. You may feel that you have not slept, even if testing shows that you have. You may also feel more fatigued than individuals without insomnia, even if testing indicates that you are less sleepy. This impaired sense of sleep may be related to a problem with the body's sleep-arousal system, which normally helps you feel awake after sleeping and feel tired before going to bed.",
"    </p>",
"    <p>",
"     One result of poor sleep is that you may become concerned that you will be sleep-deprived and will suffer from serious consequences of lost sleep. This concern may grow as you are unable to sleep, which in turn makes it increasingly difficult to fall asleep. It is important that you not get caught in this cycle and understand that you are sleeping more than it seems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      INSOMNIA CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     Insomnia may have many causes (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"      \"Types of insomnia\"",
"     </a>",
"     ):",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Short-term insomnia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Short-term insomnia lasts three months or less and is usually caused by stressors. Possible stressors include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Changes in the sleeping environment (temperature, light, noise)",
"      </li>",
"      <li>",
"       The loss of a loved one, divorce, or job loss",
"      </li>",
"      <li>",
"       Recent illness, surgery, or sources of pain",
"      </li>",
"      <li>",
"       Use or withdrawal from stimulants (caffeine), certain medications (theophylline, beta blockers, steroids, thyroid replacement, and asthma inhalers), illegal drugs (cocaine and methamphetamine), or alcohol",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Short-term insomnia often resolves when the stressor resolves.",
"    </p>",
"    <p>",
"     Traveling across time zones is another common cause of short-term insomnia, known as jet lag. Jet lag may occur regardless of the direction of travel, although it is most pronounced when traveling west to east. Most people require several days to adjust their sleep pattern to the new time zone. Other tips are provided here (",
"     <a class=\"graphic graphic_table graphicRef63656 \" href=\"UTD.htm?25/0/25611\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Insomnia is common in individuals who work the night shift (ie, third shift). You may be sleepy at work and while driving home in the morning, but have difficulty staying asleep past noon. The sleep problems can be resolved by transferring from the night shift or by sleeping at the same time every day for several weeks. Shift work sleep disorder and other sleep timing disorders are summarized in the table (",
"     <a class=\"graphic graphic_table graphicRef74802 \" href=\"UTD.htm?24/33/25115\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Long-term insomnia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Long-term insomnia lasts longer than one month. Common causes include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mental health problems, such as depression, anxiety disorders (including panic attacks), and posttraumatic stress disorder",
"      </li>",
"      <li>",
"       Medical illnesses, especially those that cause pain, stress, or difficulty breathing",
"      </li>",
"      <li>",
"       Neurological disorders, such as Parkinson disease and Alzheimer disease",
"      </li>",
"      <li>",
"       Other sleep disorders, such as sleep apnea, restless legs syndrome, sleep apnea, periodic limb movements, and circadian rhythm disorders (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"        \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Medications or illegal drug use",
"      </li>",
"      <li>",
"       Primary insomnia &ndash; Insomnia is called \"primary\" or \"independent\" if it is particularly prominent or if there is no identifiable problem causing poor sleep (",
"       <a class=\"graphic graphic_table graphicRef76668 \" href=\"UTD.htm?26/46/27372\">",
"        table 3",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Short duration sleep and sleep deprivation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Insomnia is frequently confused with short sleep requirement and sleep deprivation:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Sleeping for only a short period of time is common among people who have insomnia. However, some people normally require little sleep and can function without difficulty after sleeping for only a few hours. People who sleep less but have no residual daytime sleepiness are called short sleepers and do not have a sleep problem. In addition, you may need less sleep as you get older. Needing less sleep does not necessarily mean that you have insomnia unless you also have daytime symptoms, such as sleepiness or dysphoria.",
"      </li>",
"      <li>",
"       People who are sleep deprived as well as those with insomnia sleep for a short time and have difficulty functioning during the daytime. However, people who are sleep deprived will fall asleep quickly if given the opportunity. Chronic loss of sleep, caused by spending fewer than 8 hours in bed on most nights, is probably the most common cause of sleepiness. About one-third of adults suffer with chronic loss of sleep affects. However, not getting enough sleep is much different from insomnia, which is the inability to sleep given the chance to sleep.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      INSOMNIA DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you seek help for insomnia, your doctor or nurse will start by asking you how many hours you slept and what problems you had with sleep over a typical 24-hour period. Your bed partner or caregiver can help to answer these questions because you may not be aware of what happens while you sleep.",
"    </p>",
"    <p>",
"     You may be asked to keep a daily sleep log, which is a record of sleep times for one to two weeks (",
"     <a class=\"graphic graphic_figure graphicRef87134 \" href=\"UTD.htm?4/53/4955\">",
"      figure 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_table graphicRef87859 \" href=\"UTD.htm?13/62/14318\">",
"      table 4",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Your doctor or nurse may ask other questions to determine the cause of your insomnia. A physical examination may be performed to determine if there are medical or neurologic conditions causing or worsening your sleep problems.",
"    </p>",
"    <p>",
"     Laboratory tests may be recommended to help identify underlying medical or sleep disorders, although this is not required for everyone with insomnia. Laboratory tests may include polysomnography or actigraphy:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Polysomnography &ndash; Polysomnography is a formal sleep study done in a sleep laboratory. It uses monitors that are attached to your body to record movement, brain activity, breathing, and other physiologic functions. This test may be used when an underlying sleep disorder is suspected or if your insomnia has not responded to treatment.",
"      </li>",
"      <li>",
"       Actigraphy &ndash; Actigraphy records activity and movement with a monitor or motion detector, generally worn on the wrist throughout the day and night. The test is conducted over one to two weeks at home to gather estimates about how much and at what time you are sleeping.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      INSOMNIA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of insomnia is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"      \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804392381\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876429\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/58/22434?source=see_link\">",
"      Patient information: Insomnia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/9/15506?source=see_link\">",
"      Patient information: Nocturnal (nighttime) leg cramps (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/29/20946?source=see_link\">",
"      Patient information: Restless legs syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/34/547?source=see_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=see_link\">",
"      Patient information: Jet lag (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/5/35921?source=see_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2876421\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"      Classification of sleep disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"      Overview of insomnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13034?source=see_link\">",
"      Physiology and clinical use of melatonin",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"      Treatment of insomnia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"      Types of insomnia",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sleepdisorders.html\">",
"      www.nlm.nih.gov/medlineplus/sleepdisorders.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Sleep Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aasmnet.org/\">",
"      www.aasmnet.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/public/sleep/index.htm\">",
"      www.nhlbi.nih.gov/health/public/sleep/index.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/16/2306/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/16/2306?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Gallup Organization. Sleep in America: A National Survey of US Adults. National Sleep Foundation, Princeton, NJ, 1991.",
"    </li>",
"    <li>",
"     National Sleep Foundation. Can't sleep?: Learn about Insomnia. Available online at www.sleepfoundation.org (accessed July 19, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2306/abstract/3\">",
"      Sateia MJ, Nowell PD. Insomnia. Lancet 2004; 364:1959.",
"     </a>",
"    </li>",
"    <li>",
"     Leshner AI, Kvale JN, Baghdoyan HA. National Institutes of Health State-of-the-Science Conference Statement: Manifestations and Management of Chronic Insomnia in Adults. Available online at file://consensus.nih.gov/ta/026/InsomniaDraftStatement061505.pdf (accessed July 21, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2306/abstract/5\">",
"      Silber MH. Clinical practice. Chronic insomnia. N Engl J Med 2005; 353:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2306/abstract/6\">",
"      Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004; 164:1888.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_16_2306=[""].join("\n");
var outline_f2_16_2306=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INSOMNIA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           INSOMNIA CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           INSOMNIA DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           INSOMNIA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/53/4955\" title=\"figure 1\">",
"           [ARC]Consensus sleep diary",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?25/0/25611\" title=\"table 1\">",
"           Time zone shift PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?24/33/25115\" title=\"table 2\">",
"           Circadian rhythm disorders PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?26/46/27372\" title=\"table 3\">",
"           Independent insomnia PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?13/62/14318\" title=\"table 4\">",
"           Consensus sleep diary instructions",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2307="Subcentimeter enhancing pancreatic neuroendocrine tumor";
var content_f2_16_2307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial image of a contrast-enhanced CT scan demonstrating a subcentimeter enhancing pancreatic neuroendocrine tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2307=[""].join("\n");
var outline_f2_16_2307=null;
var title_f2_16_2308="ACC prev resect pulm mets";
var content_f2_16_2308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary metastases from previously resected adenoid cystic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James R Jett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2308=[""].join("\n");
var outline_f2_16_2308=null;
var title_f2_16_2309="Nerve conduction studies";
var content_f2_16_2309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral nerve conduction studies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 569px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Measurement of othodromic conduction in the median nerve. The left index finger is stimulate and the sensory action potential is recorded over the median nerve, proximal to the carpal tunnel. Bottom panel: Antidromic conduction is assessed in the radial nerve by proximal stimulation and distal recording. The distance between the stimulating and recording electrodes (meters) is divided by the time to the initial deflection (seconds) to give the nerve conduction velocity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2309=[""].join("\n");
var outline_f2_16_2309=null;
var title_f2_16_2310="Hypercalcemia in granulomatous diseases";
var content_f2_16_2310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypercalcemia in granulomatous diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2310/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/16/2310/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia has been described in patients with most granulomatous disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Among them, sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/3-9\">",
"     3-9",
"    </a>",
"    ] and tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/10-14\">",
"     10-14",
"    </a>",
"    ] are probably most common. Other causes include berylliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/15\">",
"     15",
"    </a>",
"    ], coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/16\">",
"     16",
"    </a>",
"    ], histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/19\">",
"     19",
"    </a>",
"    ], Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], Langerhans-cell histiocytosis (also called histiocytosis X, and including eosinophilic granuloma) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/22\">",
"     22",
"    </a>",
"    ], silicone-induced granulomas [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/23\">",
"     23",
"    </a>",
"    ], cat-scratch disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/24\">",
"     24",
"    </a>",
"    ], Wegener's granulomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/25\">",
"     25",
"    </a>",
"    ], and Pneumocystis carinii pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic card will review hypercalcemia associated with granulomatous diseases. Other disorders that lead to hypercalcemia are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21295986\">",
"    <span class=\"h1\">",
"     CLINICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of hypercalcemia are similar regardless of the etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .) Symptoms and signs of chronic hypercalcemia (nephrolithiasis, nephrocalcinosis, renal insufficiency, and polyuria due to reduced responsiveness to antidiuretic hormone) can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"     \"Renal disease in sarcoidosis\"",
"    </a>",
"    .) However, many patients with hypercalcemia and granulomatous disease are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SARCOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism responsible for the abnormal calcium metabolism in granulomatous disease has been most completely evaluated in sarcoidosis. Approximately 30 to 50 percent of patients with this disorder have hypercalciuria, and 10 to 20 percent have hypercalcemia, which is aggravated by exposure to sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Increased intestinal calcium absorption induced by high serum calcitriol concentrations (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D) is the primary abnormality, although a calcitriol-induced increase in bone resorption may also contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In normal subjects, the conversion of 25-hydroxyvitamin D (calcidiol) to calcitriol occurs via a 1-hydroxylase (CYP27B1) in the kidney proximal tubule that is under the physiologic control of parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), and the serum phosphate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    .) Hypercalcemia normally suppresses the release of PTH and therefore the production of calcitriol, but in sarcoidosis and other granulomatous diseases, activated mononuclear cells (particularly macrophages) in the lung and lymph nodes produce calcitriol from calcidiol independent of PTH [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence for extrarenal calcitriol production is threefold [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/5-8,27\">",
"     5-8,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia and serum calcitriol concentrations have been described in an anephric patient with sarcoidosis.",
"     </li>",
"     <li>",
"      Calcidiol conversion to calcitriol can be demonstrated in vitro in alveolar macrophages or lymph node tissue obtained from hypercalcemic patients with sarcoidosis.",
"     </li>",
"     <li>",
"      Production of the messenger RNA for CYP27B1, the 1-hydroxylase, is markedly increased in alveolar macrophages isolated from hypercalcemic patients with sarcoidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normally,",
"    <span class=\"nowrap\">",
"     monocytic/macrophage",
"    </span>",
"    synthesis of calcitriol is self-regulated by negative feedback to prevent excess production. In comparison, monocytes in patients with granulomatous disease both produce more calcitriol and are resistant to the normal feedback control of calcitriol production. These effects appear to be mediated by interferon-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although only 30 to 50 percent of patients with active sarcoidosis are hypercalciuric, abnormal calcitriol metabolism can be demonstrated in some who are normocalciuric and normocalcemic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/29\">",
"     29",
"    </a>",
"    ]. As an example, increasing calcium intake appropriately lowers serum calcitriol concentrations in normal subjects but not in patients with sarcoidosis.",
"   </p>",
"   <p>",
"    Parathyroid-hormone-related protein (PTHrP), the usual etiologic agent of humoral hypercalcemia of malignancy, may also contribute to the hypercalcemia in some patients with sarcoidosis. In one series, PTHrP was found in 85 percent (17 of 20) of biopsies of granulomatous tissue from patients with sarcoidosis, and a few patients with both sarcoidosis and hypercalcemia had high serum PTHrP concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia in association with high serum calcitriol concentrations has also been described in patients with tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/12,13,31\">",
"     12,13,31",
"    </a>",
"    ]. Activated macrophages in granulomas are the most likely source of the high calcitriol levels. As in sarcoidosis, hypercalciuria due to hyperabsorption of dietary calcium is more common than overt hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of tuberculosis as a cause of hypercalcemia in such patients will vary with the population studied. In some reports, the incidence of hypercalcemia has been reported to be as high as 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/10,13\">",
"     10,13",
"    </a>",
"    ], whereas other studies suggest a much lower incidence (2.3 percent or less) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In a series of hospitalized hypercalcemic patients in Hong Kong, tuberculosis was thought to be the cause of hypercalcemia in 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible explanation for the discrepancy in incidence may lie in regional differences in vitamin D status and calcium intake. Patients who live in areas with low rates of hypercalcemia have either low dietary calcium intake or low vitamin D intake, while those who live in regions with high rates have relatively high levels of dietary calcium and vitamin D [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COCCIDIOIDOMYCOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of hypercalcemia in patients with coccidioidomycosis is unclear. In one study of 13 patients, there was no evidence of increased production of 1,25-dihydroxyvitamin D in the seven patients in whom it was measured [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, PTH levels, which were assessed in nine individuals, were normal in six and suppressed in three.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the hypercalcemia or hypercalciuria in granulomatous disorders is aimed at treatment of the underlying disorder and reducing intestinal calcium absorption and calcitriol synthesis. These can be achieved by reducing calcium intake (no more than 400",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    reducing oxalate intake, elimination of dietary vitamin D supplements, and avoidance of sun exposure.",
"   </p>",
"   <p>",
"    In addition to these measures, low-dose glucocorticoid therapy (10 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) is typically used to treat sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/37\">",
"     37",
"    </a>",
"    ]. The serum calcium concentration begins to fall in two days, but the full hypocalcemic response may take 7 to 10 days depending upon the prednisone dose. Inhibition of calcitriol synthesis by the activated mononuclear cells is thought to play a major role in this response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], although inhibition of intestinal calcium absorption and of osteoclast activity also may contribute.",
"   </p>",
"   <p>",
"    Concurrent restriction of dietary oxalate is required to prevent a marked increase in oxalate absorption and hyperoxaluria; the latter may increase the risk of kidney stone formation even though urinary calcium excretion is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/39\">",
"     39",
"    </a>",
"    ]. Oxalate absorption is normally limited by the formation of insoluble calcium oxalate salts in the intestinal lumen. Dietary calcium restriction leads to more free oxalate that can then be absorbed if oxalate intake is unchanged. Another treatment for recurrent calcium stones due to hypercalciuria, a thiazide diuretic, is contraindicated in sarcoidosis, since it can sequentially lead to reduced calcium excretion, calcium retention, and hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with sarcoid who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be effectively treated with a general inhibitor of P450 enzymes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , to decrease calcitriol production. This approach is a second line therapy recommended for patients intolerant or refractory to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Some reports describe a series of patients treated with the anti-TNF monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , with promising results, although hypercalcemia was not discussed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/43\">",
"     43",
"    </a>",
"    ]. Alternative therapies for hypercalcemia include bisphosphonates such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or an antimalarial drug such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , or perhaps the less toxic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/9,44-46\">",
"     9,44-46",
"    </a>",
"    ]. The latter two drugs act by decreasing the inflammatory activity of the disease.",
"   </p>",
"   <p>",
"    For patients with tuberculosis, coccidioidomycosis, or other underlying infectious etiology, treatment with antibiotics or antifungal agents is necessary. Glucocorticoids and bisphosphonates have also been used successfully in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2310/abstract/36,47,48\">",
"     36,47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"     \"Treatment of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21338621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercalcemia has been described in patients with granulomatous disorders, most commonly sarcoidosis and tuberculosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypercalcemia in sarcoidosis and other granulomatous diseases is due to PTH-independent extrarenal production of calcitriol from calcidiol by activated mononuclear cells (particularly macrophages) in the lung and lymph nodes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sarcoidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to treatment of the underlying disorder, treatment of hypercalcemia or hypercalciuria is aimed at reducing intestinal calcium absorption and calcitriol synthesis. These can be achieved by reducing calcium intake (no more than 400",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      reducing oxalate intake, elimination of dietary vitamin D supplements, and avoidance of sun exposure. Glucocorticoids and bisphosphonates have also been used successfully to treat hypercalcemia in granulomatous diseases. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link\">",
"       \"Treatment of hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/1\">",
"      Adams JS. Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am 1989; 18:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/2\">",
"      Jacobs TP, Bilezikian JP. Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab 2005; 90:6316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/3\">",
"      Winnacker JL, Becker KL, Katz S. Endocrine aspects of sarcoidosis. N Engl J Med 1968; 278:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/4\">",
"      Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest 1996; 109:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/5\">",
"      Adams JS, Sharma OP, Gacad MA, Singer FR. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983; 72:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/6\">",
"      Adams JS, Singer FR, Gacad MA, et al. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 1985; 60:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/7\">",
"      Mason RS, Frankel T, Chan YL, et al. Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med 1984; 100:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/8\">",
"      Insogna KL, Dreyer BE, Mitnick M, et al. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. J Clin Endocrinol Metab 1988; 66:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/9\">",
"      Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med 1989; 111:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/10\">",
"      Abbasi AA, Chemplavil JK, Farah S, et al. Hypercalcemia in active pulmonary tuberculosis. Ann Intern Med 1979; 90:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/11\">",
"      Shai F, Baker RK, Addrizzo JR, Wallach S. Hypercalcemia in mycobacterial infection. J Clin Endocrinol Metab 1972; 34:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/12\">",
"      Gkonos PJ, London R, Hendler ED. Hypercalcemia and elevated 1,25-dihydroxyvitamin D levels in a patient with end-stage renal disease and active tuberculosis. N Engl J Med 1984; 311:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/13\">",
"      Cadranel J, Garabedian M, Milleron B, et al. 1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J Clin Invest 1990; 85:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/14\">",
"      Shek CC, Natkunam A, Tsang V, et al. Incidence, causes and mechanism of hypercalcaemia in a hospital population in Hong Kong. Q J Med 1990; 77:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/15\">",
"      Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/16\">",
"      Lee JC, Catanzaro A, Parthemore JG, et al. Hypercalcemia in disseminated coccidioidomycosis. N Engl J Med 1977; 297:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/17\">",
"      Murray JJ, Heim CR. Hypercalcemia in disseminated histoplasmosis. Aggravation by vitamin D. Am J Med 1985; 78:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/18\">",
"      Kamili Qu, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 2010; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/19\">",
"      Kantarjian HM, Saad MF, Estey EH, et al. Hypercalcemia in disseminated candidiasis. Am J Med 1983; 74:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/20\">",
"      Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. Gastroenterology 1998; 114:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/21\">",
"      Tuohy KA, Steinman TI. Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease. Am J Kidney Dis 2005; 45:e3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/22\">",
"      Jurney TH. Hypercalcemia in a patient with eosinophilic granuloma. Am J Med 1984; 76:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/23\">",
"      Kozeny GA, Barbato AL, Bansal VK, et al. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med 1984; 311:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/24\">",
"      Bosch X. Hypercalcemia due to endogenous overproduction of active vitamin D in identical twins with cat-scratch disease. JAMA 1998; 279:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/25\">",
"      Edelson, GW, Talpos, GB, Bone HG. Hypercalcemia associated with Wegener's granulomatosis and hyperparathyroidism: etiology and management. Am J Nephrol 1993; 13:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/26\">",
"      Ahmed B, Jaspan JB. Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci 1993; 306:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/27\">",
"      Inui N, Murayama A, Sasaki S, et al. Correlation between 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in alveolar macrophages and the activity of sarcoidosis. Am J Med 2001; 110:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/28\">",
"      Dusso AS, Kamimura S, Gallieni M, et al. gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. J Clin Endocrinol Metab 1997; 82:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/29\">",
"      Basile JN, Liel Y, Shary J, Bell NH. Increased calcium intake does not suppress circulating 1,25-dihydroxyvitamin D in normocalcemic patients with sarcoidosis. J Clin Invest 1993; 91:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/30\">",
"      Zeimer HJ, Greenaway TM, Slavin J, et al. Parathyroid-hormone-related protein in sarcoidosis. Am J Pathol 1998; 152:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/31\">",
"      Kuno Y, Iyoda M, Aoshima Y, et al. A case of tuberculous peritonitis in a hemodialysis patient with high serum soluble interleukin-2 receptor and CA-125 levels. Intern Med 2010; 49:1783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/32\">",
"      Martinez ME, Gonzalez J, Sanchez-Cabezudo MJ, et al. Evidence of absorptive hypercalciuria in tuberculosis patients. Calcif Tissue Int 1993; 53:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/33\">",
"      Tan TT, Lee BC, Khalid BA. Low incidence of hypercalcaemia in tuberculosis in Malaysia. J Trop Med Hyg 1993; 96:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/34\">",
"      Keletimur F, G&uuml;ven M, Ozesmi M, Paaolu H. Does tuberculosis really cause hypercalcemia? J Endocrinol Invest 1996; 19:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/35\">",
"      Chan TY. Differences in vitamin D status and calcium intake: possible explanations for the regional variations in the prevalence of hypercalcemia in tuberculosis. Calcif Tissue Int 1997; 60:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/36\">",
"      Caldwell JW, Arsura EL, Kilgore WB, et al. Hypercalcemia in patients with disseminated coccidioidomycosis. Am J Med Sci 2004; 327:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/37\">",
"      Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993; 82:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/38\">",
"      Sandler LM, Winearls CG, Fraher LJ, et al. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3. Q J Med 1984; 53:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/39\">",
"      Kogan BA, Konnak JW, Lau K. Marked hyperoxaluria in sarcoidosis during orthophosphate therapy. J Urol 1982; 127:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/40\">",
"      Conron M, Beynon HL. Ketoconazole for the treatment of refractory hypercalcemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/41\">",
"      Adams JS, Sharma OP, Diz MM, Endres DB. Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 1990; 70:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/42\">",
"      Tercelj M, Rott T, Rylander R. Antifungal treatment in sarcoidosis--a pilot intervention trial. Respir Med 2007; 101:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/43\">",
"      Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/44\">",
"      O'Leary TJ, Jones G, Yip A, et al. The effects of chloroquine on serum 1,25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 1986; 315:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/45\">",
"      Barr&eacute; PE, Gascon-Barr&eacute; M, Meakins JL, Goltzman D. Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis. Am J Med 1987; 82:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/46\">",
"      Gibbs CJ, Peacock M. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Postgrad Med J 1986; 62:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/47\">",
"      Westphal SA. Disseminated coccidioidomycosis associated with hypercalcemia. Mayo Clin Proc 1998; 73:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2310/abstract/48\">",
"      Rizwan A, Islam N. Middle aged male with pulmonary tuberculosis and refractory hypercalcemia at a tertiary care centre in South East Asia: a case report. Cases J 2009; 2:6316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 841 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2310=[""].join("\n");
var outline_f2_16_2310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21338621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21295986\">",
"      CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SARCOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COCCIDIOIDOMYCOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21338621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2311="Ezetimibe and simvastatin: Pediatric drug information";
var content_f2_16_2311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ezetimibe and simvastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/4/41031?source=see_link\">",
"    see \"Ezetimibe and simvastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43493?source=see_link\">",
"    see \"Ezetimibe and simvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vytorin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholesterol Absorption Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HMG-CoA Reductase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/4/41031?source=see_link\">",
"      see \"Ezetimibe and simvastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Homozygous familial hypercholesterolemia: Children &ge;10 years and Adults: Ezetimibe 10 mg/simvastatin 40 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hyperlipidemia: Adults: Initial: 10 mg ezetimibe/20 mg simvastatin once daily in the evening; patients requiring less aggressive LDL-C reductions may be started on 10 mg ezetimibe/10 mg simvastatin; patients who require a reduction of &gt;55% in LDL-C may be started at 10 mg ezetimibe/40 mg simvastatin once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant amiodarone, diltiazem, or verapamil:",
"     </b>",
"     Adults: The daily dose should not exceed 10 mg ezetimibe/10 mg simvastatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant amlodipine or ranolazine:",
"     </b>",
"     Adults: The daily dose should not exceed 10 mg ezetimibe/20 mg simvastatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults: Because simvastatin does not undergo significant renal excretion, modification of dose should only be necessary in patients with severe renal impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Not for use unless the patient has tolerated simvastatin at a dose of &ge;5 mg, the daily dose should not to exceed 10 mg ezetimibe/10 mg simvastatin",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/10: Ezetimibe 10 mg and simvastatin 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/20: Ezetimibe 10 mg and simvastatin 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/40: Ezetimibe 10 mg and simvastatin 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vytorin&reg; 10/80: Ezetimibe 10 mg and simvastatin 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals. Administration with the evening meal or at bedtime has been associated with somewhat greater LDL-C reduction.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be stored in well closed containers at temperatures between 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hyperlipidemia: Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels, and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb); treatment of homozygous familial hypercholesterolemia; treatment of isolated hypertriglyceridemia (Fredrickson type IV) and type III hyperlipoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Primary prevention of cardiovascular disease in high risk patients; risk factors include: Age &gt;55 years, smoking, hypertension, low HDL-C, or family history of early coronary heart disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vytorin&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, pain in extremity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Influenza",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to simvastatin, ezetimibe, or any component; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, HIV protease inhibitors, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin), cyclosporine, danazol, and gemfibrozil",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Persistent increases in serum transaminases have occurred; liver function must be monitored by laboratory assessment at the initiation of therapy and periodically thereafter for the first year of treatment or until one year after the last elevation in dose. Use with caution in patients who consume substantial quantities of alcohol or have a previous history of liver disease. Use with caution in patients with diabetes mellitus and renal impairment (may be at increased risk for developing rhabdomyolysis).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rhabdomyolysis with acute renal failure has occurred. Risk is dose-related and is increased with concurrent use of lipid-lowering agents which may also cause rhabdomyolysis (gemfibrozil, other fibric acid derivatives, or niacin at doses &ge;1 g/day), and concurrent use of other interacting medications (eg, amiodarone, grapefruit juice in large quantities, verapamil). Monitor closely if used with other drugs associated with myopathy (eg, colchicine). Assess the risk versus benefit when combining any of these drugs with simvastatin. Concomitant use of high-dose simvastatin (80 mg) with niacin &ge;1 g/day may increase risk of myopathy in Chinese patients. A lowered dosage of simvastatin is recommended when used with medications which may increase risk of rhabdomyolysis. Advise patients to promptly report any unexplained muscle pain, tenderness, or weakness. Temporarily discontinue Vytorin&trade; in any patient experiencing in any patient experiencing unexplained muscle pain, tenderness or weakness, and/or CPK level &gt;10 times the normal range. Monitor CPK periodically in patients with complicated medical histories including renal insufficiency.",
"     <b>",
"      High dose (80 mg) is limited to patients who  have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F169638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Simvastatin serum concentration may be increased when taken with large quantities (&gt;1 quart/day) of grapefruit juice; avoid concurrent use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Creatine phosphokinase levels due to possibility of myopathy; serum cholesterol (total and fractionated)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Obtain liver function tests prior to initiation, dosage increase, and thereafter when clinically indicated. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize. Discontinue if increase in ALT/AST is persistently &gt;3 times ULN.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine. Simvastatin is a methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &gt;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: After 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43493?source=see_link\">",
"      see \"Ezetimibe and simvastatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight. Report severe and unresolved gastric upset, any vision changes, muscle pain and weakness, changes in color of urine or stool, yellowing of skin or eyes, and any unusual bruising. Female patients of childbearing age must be counseled to use 2 effective forms of contraception simultaneously, unless absolute abstinence is the chosen method; this drug may cause severe fetal defects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Nutrition, &ldquo;Cholesterol in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1 Pt 1):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/11345978/pubmed\" id=\"11345978\" target=\"_blank\">",
"        11345978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics, National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(3 Pt 2):525-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/1538956 /pubmed\" id=\"1538956 \" target=\"_blank\">",
"        1538956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dejongh S, Stalenhoef AF, Tuohy MB, et al, &ldquo;Efficacy, Safety, and Tolerability of Simvastatin in Children With Familial Hypercholesterolemia: Rational, Design and Baseline Characterisitics ,&rdquo;",
"      <i>",
"       Clin Drug Invest",
"      </i>",
"      , 2002, 22(8):533-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ducobu J, Brasseur D, Chaudron JM, et al, &ldquo;Simvastatin Use in Children,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 339(8807):1488.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/1351171/pubmed\" id=\"1351171\" target=\"_blank\">",
"        1351171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duplaga BA, &ldquo;Treatment of Childhood Hypercholesterolemia With HMG-CoA Reductase Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(11):1224-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/10573325 /pubmed\" id=\"10573325 \" target=\"_blank\">",
"        10573325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gagne C, Gaudet D, Bruckert E, et al, &ldquo;Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(21):2469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/12034651 /pubmed\" id=\"12034651 \" target=\"_blank\">",
"        12034651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(2):227-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/ 15249516 /pubmed\" id=\" 15249516 \" target=\"_blank\">",
"        15249516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/16/2311/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12928 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2311=[""].join("\n");
var outline_f2_16_2311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169626\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058634\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058628\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169612\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169601\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058638\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058630\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058637\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169648\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058642\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058627\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058626\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169638\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169607\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058645\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169609\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169619\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058633\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058625\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058640\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058641\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058632\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12928\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12928|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/4/41031?source=related_link\">",
"      Ezetimibe and simvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/30/43493?source=related_link\">",
"      Ezetimibe and simvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2312="Screening for diabetes mellitus";
var content_f2_16_2312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2312/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2312/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2312/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2312/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2312/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/16/2312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following five criteria define the optimal conditions for screening for a particular disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The disorder should be an important public health problem",
"     </li>",
"     <li>",
"      An early asymptomatic stage should exist",
"     </li>",
"     <li>",
"      There is a suitable screening test",
"     </li>",
"     <li>",
"      An accepted treatment should be available",
"     </li>",
"     <li>",
"      There is evidence that early treatment during the asymptomatic stage improves long-term outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent to which these criteria are met for type 1 and type 2 diabetes mellitus is reviewed here, as well as practical recommendations on how to screen for these disorders in clinical practice. Screening of pregnant women for gestational diabetes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE 1 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of type 1 diabetes continues to increase around the world, although it still affects less than 0.5 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/2\">",
"     2",
"    </a>",
"    ]. An early asymptomatic phase exists; many subjects in this phase can be identified, but only by a combination of immunologic, genetic, and metabolic tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no accepted treatment for the asymptomatic phase of type 1 diabetes. In the Diabetes Prevention Trial (DPT), parenteral insulin therapy did not prevent type 1 diabetes in high-risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, routine screening for type 1 diabetes cannot be recommended except for research purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arguments for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has not been established that",
"    <strong>",
"     early",
"    </strong>",
"    detection of type 2 diabetes and intervention improve long-term outcomes. (See",
"    <a class=\"local\" href=\"#H2377257\">",
"     'Effectiveness of early detection'",
"    </a>",
"    below.) However, the arguments for widespread screening to identify undiagnosed cases of type 2 diabetes are much stronger than for type 1 diabetes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 2 diabetes is a major public health problem affecting approximately 8 percent of the United States (US) population and with as many as 25 percent of the population remaining undiagnosed [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/3\">",
"       3",
"      </a>",
"      ]. Data from the Framingham Heart Study indicate that the incidence of type 2 diabetes has doubled over the last 30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/4\">",
"       4",
"      </a>",
"      ]. The global prevalence of type 2 diabetes continues to rise [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An asymptomatic period exists.",
"     </li>",
"     <li>",
"      There is debate about the ideal screening test, but measurement of glycated hemoglobin (A1C), fasting blood glucose (or, under some circumstances, random blood glucose or two-hour post-glucose challenge) is adequate for identifying many undiagnosed cases of diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Persons at high-risk for the development of diabetes can be identified efficiently during screening for undiagnosed type 2 diabetes using the same measurements of glycemia.",
"     </li>",
"     <li>",
"      Undiagnosed diabetes can cause progressive microvascular damage. At the time of diagnosis, approximately 20 percent of newly diagnosed patients with type 2 diabetes have diabetic retinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/10\">",
"       10",
"      </a>",
"      ] and 10 percent have nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=see_link\">",
"       \"Classification and clinical features of diabetic retinopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=see_link\">",
"       \"Microalbuminuria in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Delayed diagnosis translates into more organ damage since effective therapy cannot be applied. The Diabetes Control and Complications Trial (DCCT) demonstrated that interventions that improve glycemic control in patients with type 1 diabetes reduce the risk of development and slow the progression of diabetic microvascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/12\">",
"       12",
"      </a>",
"      ]. The United Kingdom Prospective Diabetes Study (UKPDS) showed that strict glycemic control has a similar benefit in patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"       \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Well-established treatments for type 2 diabetes exist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"       \"Overview of medical care in adults with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lifestyle intervention programs aimed at weight loss and increased activity levels, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      and other medications reduce the risk of type 2 diabetes in patients with impaired glucose tolerance (IGT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Screening tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used screening tests for type 2 diabetes include measurement of fasting plasma glucose (FPG), two-hour plasma glucose during an oral glucose tolerance test (2-h OGTT), and glycated hemoglobin (A1C) (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"UTD.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The sensitivity and specificity of FPG and A1C as screening tests vary according to the population tested and the threshold used to define diabetes. Using a two-hour blood glucose &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    on an oral glucose tolerance test as the reference standard, the specificity of a fasting blood glucose &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was greater than 95 percent; the sensitivity was about 50 percent, and may be lower for people over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/14\">",
"     14",
"    </a>",
"    ]. Using the same reference standard, the specificity and sensitivity of an A1C cut point of 6.5 percent were 79 and 44 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the presence of diabetic retinopathy correlated better with A1C &ge;6.5 percent than with FPG or OGTT criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Blood glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose values are distributed over a continuum in the population, although there are some approximate thresholds above which the risk of future adverse events is substantial. An Expert Committee on the Diagnosis and Classification of Diabetes Mellitus recommended placing individuals in one of three categories based upon the fasting plasma glucose concentration, A1C, or 2-h OGTT (75 gram glucose load) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/3,8,16\">",
"     3,8,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Hemoglobin A1C'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal &mdash; Fasting plasma glucose (FPG) &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Fasting is defined as no caloric intake for at least eight hours.",
"     </li>",
"     <li>",
"      Increased risk for diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Impaired fasting glucose (IFG) &mdash; Fasting plasma glucose between 100 and 125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6 to 6.9",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      Impaired glucose tolerance (IGT) &mdash; Two hour plasma glucose value during a 75 gram oral glucose tolerance test between 140 and 199",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.8 to 11.0",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes mellitus &mdash; FPG at or above 126",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (7.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      A1C &ge;6.5 percent, a two-hour value in an OGTT (2-h PG) at or above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or a random (or \"casual\") plasma glucose concentration &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the presence of symptoms. The diagnosis of diabetes must be confirmed on a subsequent day by repeat measurement, repeating the same test for confirmation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"       \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with diabetes mellitus are at increased risk for both microvascular and macrovascular disease. The diagnostic glucose levels were selected based upon the attendant risk for developing the relatively specific long-term complication of retinopathy. Those with impaired fasting blood glucose are at increased risk for macrovascular disease (myocardial infarction, stroke, peripheral vascular disease), but generally not for microvascular disease (retinopathy, neuropathy and nephropathy), unless they go on to develop diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hemoglobin A1C",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been long-standing interest in the use of glycated hemoglobin (A1C) values for screening and identification of impaired glucose tolerance and diabetes. An International Expert Committee issued a consensus report in June 2009, recommending that an A1C level &ge;6.5 percent be used to diagnose diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/8\">",
"     8",
"    </a>",
"    ], and the ADA affirmed this decision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients with A1C values between 6.0 and 6.4 percent were considered to be at particularly high risk for developing diabetes, although the risk is a continuum across the entire spectrum of subdiabetic A1C levels. The ADA selected 5.7 to 6.4 percent to represent increased risk for developing diabetes (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 2",
"    </a>",
"    ). The diagnosis should be confirmed with a repeat A1C measurement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In making the recommendation, the report noted several technical advantages of the A1C assay over glucose testing, increased patient convenience (since there is no special preparation or timing required for the A1C test), and the correlation of A1C levels with retinopathy. The report also noted that if an A1C test is either unavailable or uninterpretable, for example owing to rapid red cell turnover with anemia, the previous diagnostic methods and criteria, using glucose testing, should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of diabetes mellitus\", section on 'Hemoglobin A1C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link&amp;anchor=H5#H5\">",
"     \"Estimation of blood glucose control in diabetes mellitus\", section on 'Sources of error'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Urine glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of glucose on a semiquantitative urine dipstick (anything regarded as trace positive or more) or Clinitest tablets is an insensitive means of screening for type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/18\">",
"     18",
"    </a>",
"    ]. The high rate of false-negative results suggests that the urine dipstick is not adequate as a screening test. Additionally, not all patients with glucosuria have diabetes. Glucosuria can occur with defects in renal tubular function, as seen in Type 2 (proximal) renal tubular acidosis and in familial renal glucosuria, a genetic disorder associated with salt-wasting, polyuria, and volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, patients with glucosuria require blood testing (A1C, FPG, or 2h-OGTT) for diagnosis of diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2377257\">",
"    <span class=\"h2\">",
"     Effectiveness of early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost-effectiveness analyses have suggested that diabetes screening in older adults is cost-effective. As an example, in a computer simulation model, eight screening strategies were compared with a no-screening control strategy in a simulated population of 325,000 people aged 30 years without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/20\">",
"     20",
"    </a>",
"    ]. The benefits of early detection for all screening strategies included a reduced incidence of myocardial infarction and microvascular complications and an increase in quality-adjusted life years (QALYs) over 50 years of age. The most cost-effective strategies were those that started between the ages of 30 and 45 years, with screening repeated every three to five years. The model assumed perfect performance and compliance with treatment recommendations. Outcomes in a real clinical setting would likely not be as good.",
"   </p>",
"   <p>",
"    In other cost-effectiveness analyses, screening targeted to individuals with hypertension was more cost-effective than universal screening [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/21\">",
"     21",
"    </a>",
"    ], and screening for impaired glucose tolerance (prediabetes) and undiagnosed type 2 diabetes, followed by intervention (lifestyle or pharmacological), was more cost-effective than no screening [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/22\">",
"     22",
"    </a>",
"    ]. In one model, the most cost-effective strategy was targeted screening at age 55 to 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the gold standard that would support screening for type 2 diabetes is the demonstration in a well-designed randomized trial that screening reduces important health outcomes, such as microvascular complications, cardiovascular disease, and mortality. Determining the relative effectiveness of screening would also depend upon risk factor analysis and identification of candidates for screening, the ability of the clinician to prescribe appropriate treatment, and the compliance of the patient. There are few trials evaluating the benefits of screening for type 2 diabetes. In one trial, 33 general practices in the United Kingdom were randomly assigned to screening followed by intensive multifactorial treatment of people diagnosed with diabetes, screening followed by routine care of diabetes, and a no-screening control group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/23\">",
"     23",
"    </a>",
"    ]. Individuals were selected for participation in the screening program based upon a risk score, which was calculated based upon age, gender, body mass index, family and smoking history, and steroid and antihypertensive medication use. The intensively treated group was treated to achieve an A1C &lt;7 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , plus a second or third medication (sulfonylurea, thiazolidinedione, prandial glucose regulator) as needed. Insulin was added if A1C remained above 6.5 percent. In addition, blood pressure and lipid control were important features of the intensively treated group. The routine care group received usual diabetes care through the UK National Health Service, which also focused on glycemic control and cardiovascular risk reduction.",
"   </p>",
"   <p>",
"    There were 11,271 and 4137 high risk patients, in the combined screening and no screening groups, respectively. After a median follow-up was 9.6 years, there was no difference in overall mortality (10.50 and 9.89 deaths per 1000 person-years, respectively, HR 1.06, 95% CI 0.90-1.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/23\">",
"     23",
"    </a>",
"    ]. There was also no difference in diabetes-related mortality, cardiovascular mortality, cancer mortality, or other causes of death. Differences between the screening and no screening groups in long-term microvascular (eg, retinopathy, kidney disease) and coronary heart disease events were not reported. Limitations of this trial include a low overall prevalence of newly diagnosed diabetes (3 percent of screened population) and the lack of data on outcomes in patients with screen-detected diabetes compared with patients diagnosed through routine clinical care. Furthermore, the long-term complications of diabetes require more than a decade of diabetes to develop, with morbidity or mortality associated with the complications requiring substantially more time. Thus, a study with only a decade of follow-up is too brief to demonstrate the potential benefit(s) of screening in this chronic degenerative disease. Additional trials examining morbidity and quality of life issues between screen-detected diabetes and diagnosis through routine clinical care are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Screening recommendations by expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two approaches to screening that are usually recommended (and are not mutually exclusive) are either to screen the entire population above a certain age, or to screen certain \"high-risk\" groups. The ADA recommends testing for diabetes or prediabetes in all adults with BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    and one or more additional risk factors for diabetes (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk factors'",
"    </a>",
"    below). In individuals without risk factors, testing should begin at age 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/9\">",
"     9",
"    </a>",
"    ]. Either A1C, fasting plasma glucose, or 2-h OGTT is appropriate for testing. If the tests are normal, the patient should be retested in three years.",
"   </p>",
"   <p>",
"    If the fasting blood glucose concentration is above 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the test should be repeated. Two fasting blood glucose values &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    two A1C values &ge;6.5 percent, two post-glucose values over 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or one each of two of the above, or a random glucose &ge;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with symptoms of diabetes is required to make the diagnosis of diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force concluded that there was insufficient evidence to recommend for or against screening for diabetes in nonpregnant adults without hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/24\">",
"     24",
"    </a>",
"    ]. This conclusion was based primarily on the lack of evidence that earlier detection of diabetes improves long-term outcomes. However, the task force found that there was moderate evidence for and recommended screening in adults with hypertension (blood pressure",
"    <span class=\"nowrap\">",
"     &gt;135/80",
"    </span>",
"    mmHg) as part of an integrated approach to reduce cardiovascular risk. The USPSTF clinical practice guideline for screening for type 2 diabetes mellitus in adults, as well as other USPSTF guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     Agency for Healthcare Research and Quality website",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The Canadian Task Force on the Periodic Health Examination recommends screening adults with hypertension and hyperlipidemia for type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective analysis comparing the case-finding ability of the ADA versus the USPSTF screening guidelines, the ADA criteria classified more patients as eligible for screening (66 versus 26 percent with USPSTF screening criteria) and missed fewer diagnoses (4 versus 38 percent of the 1390 patients diagnosed as having diabetes) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes risk factors include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ge;45 years",
"     </li>",
"     <li>",
"      Overweight (body mass index &ge;25",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"     </li>",
"     <li>",
"      Family history diabetes mellitus in a first-degree relative",
"     </li>",
"     <li>",
"      Habitual physical inactivity",
"     </li>",
"     <li>",
"      Belonging to a high-risk ethnic or racial group (eg, African-American, Hispanic, Native American, Asian-American, and Pacific Islanders)",
"     </li>",
"     <li>",
"      History of delivering a baby weighing &gt;4.1 kg (9 lb) or of gestational diabetes mellitus",
"     </li>",
"     <li>",
"      Hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;140/90",
"      </span>",
"      mmHg)",
"     </li>",
"     <li>",
"      Dyslipidemia defined as a serum high-density lipoprotein cholesterol concentration &le;35",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a serum triglyceride concentration &ge;250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Previously identified A1C &ge;5.7 percent, impaired glucose tolerance or impaired fasting glucose",
"     </li>",
"     <li>",
"      Polycystic ovary syndrome",
"     </li>",
"     <li>",
"      History of vascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Calculating a risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factor assessment scoring systems have been investigated as a strategy to guide screening, but most have not been validated in diverse populations, and they are not in widespread use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The majority of these risk assessment tools involve simple questionnaires about important diabetes risk factors (eg, age, weight, family history of diabetes, personal history of hypertension, physical activity). A score is assigned for each risk factor and the total score used to identify individuals for laboratory screening. Depending upon the cut-point used, sensitivity and specificity for predicting undiagnosed diabetes are approximately 80 and 70 percent, respectively.",
"   </p>",
"   <p>",
"    The above scoring systems were devised to guide screening. Other more complex models using risk factor assessment combined with laboratory testing have been devised to predict the likelihood of developing type 2 diabetes. These models are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H7#H7\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Prediction models'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     A suggested approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with ADA guidelines, we recommend measurement of fasting plasma glucose or A1C in individuals who are considered high risk (BMI &ge;25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    with one or more additional risk factors for diabetes) and everyone aged 45 years or older receiving health care (or maintenance). Among such patients seeking health care who have not fasted overnight, A1C is the preferred test. A FPG value &le;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or A1C &lt;5.7 percent should be considered normal and the patient should be retested in three years. For patients at increased risk for diabetes (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 2",
"    </a>",
"    ), monitoring for the development of diabetes should be performed yearly.",
"   </p>",
"   <p>",
"    If the fasting blood glucose value is above 126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or the A1C is &ge;6.5 percent, the initial test should be repeated. The diagnosis of diabetes is confirmed if two consecutive A1C levels are &ge;6.5 percent, two consecutive FPG levels are &gt;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or if both the A1C and FPG are above their diagnostic thresholds (",
"    <a class=\"graphic graphic_table graphicRef61853 \" href=\"UTD.htm?28/3/28731\">",
"     table 1",
"    </a>",
"    ). If A1C and FPG are discordant, the test that is diagnostic of diabetes should be repeated to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients meeting the criteria for diagnosis of diabetes or increased risk for diabetes (",
"    <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"     table 2",
"    </a>",
"    ) should be counseled vigorously on issues related to lowering their risk of macrovascular disease (smoking cessation, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , diet, and exercise), and should have measurements of blood pressure and serum lipids. They should also be encouraged to modify their lifestyle with increased exercise (ideally 150 minutes weekly) and weight reduction, targeting a 7 percent weight loss if overweight, as these measures have been shown to significantly decrease the risk of developing type 2 diabetes and to improve outcomes in those with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2312/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Indications for pharmacologic intervention are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H9#H9\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Lifestyle modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H19#H19\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Pharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     \"Overview of medical care in adults with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=see_link\">",
"       \"Patient information: Hemoglobin A1C tests (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"       \"Patient information: Preventing type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine screening for type 1 diabetes is not recommended. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Type 1 diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with risk factors for type 2 diabetes, we suggest screening (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Candidates for screening include adults with a BMI &ge;25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      who have one or more additional risk factors for diabetes (eg, family history diabetes mellitus in a first-degree relative, habitual physical inactivity, gestational diabetes, hypertension, dyslipidemia). For adults without risk factors, we suggest that screening begin at age &gt;45 years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'A suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either glycated hemoglobin (A1C), fasting plasma glucose (FPG), or 2-h 75 g OGTT are appropriate screening tests. Among candidates for screening who have not fasted overnight, A1C is the preferred test. Repeat measurement is required to confirm diagnosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'A suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with normal A1C or FPG, we suggest a follow-up measurement in three years (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'A suggested approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients meeting the criteria for diagnosis of diabetes (",
"      <a class=\"graphic graphic_table graphicRef61853 \" href=\"UTD.htm?28/3/28731\">",
"       table 1",
"      </a>",
"      ) or increased risk for diabetes (",
"      <a class=\"graphic graphic_table graphicRef82479 \" href=\"UTD.htm?1/61/2011\">",
"       table 2",
"      </a>",
"      ) should be counseled vigorously on issues related to lowering their risk of macrovascular disease (smoking cessation, use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , diet, and exercise), and should have measurements of blood pressure and serum lipids. Indications for pharmacologic intervention are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"       \"Overview of medical care in adults with diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H9#H9\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Lifestyle modification'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H19#H19\">",
"       \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wilson, JM, Junger, G. Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968.",
"    </li>",
"    <li>",
"     CDC. National Diabetes Fact Sheet, 2007. file://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf (Accessed on January 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/3\">",
"      American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/4\">",
"      Fox CS, Pencina MJ, Meigs JB, et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006; 113:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/5\">",
"      Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/6\">",
"      Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/7\">",
"      Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2&middot;7 million participants. Lancet 2011; 378:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/8\">",
"      International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/9\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/10\">",
"      Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/11\">",
"      Klein R, Klein BE, Moss S, DeMets DL. Proteinuria in diabetes. Arch Intern Med 1988; 148:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/12\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/13\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/14\">",
"      Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. Diabetes Care 1991; 14:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/15\">",
"      Kramer CK, Araneta MR, Barrett-Connor E. A1C and diabetes diagnosis: The Rancho Bernardo Study. Diabetes Care 2010; 33:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/16\">",
"      Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/17\">",
"      American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 Suppl 1:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/18\">",
"      Andersson DK, Lundblad E, Sv&auml;rdsudd K. A model for early diagnosis of type 2 diabetes mellitus in primary health care. Diabet Med 1993; 10:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/19\">",
"      Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006; 69:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/20\">",
"      Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/21\">",
"      Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/22\">",
"      Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 336:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/23\">",
"      Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012; 380:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/24\">",
"      U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/25\">",
"      Feig DS, Palda VA, Lipscombe L, Canadian Task Force on Preventive Health Care. Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2005; 172:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/26\">",
"      Sheehy AM, Flood GE, Tuan WJ, et al. Analysis of guidelines for screening diabetes mellitus in an ambulatory population. Mayo Clin Proc 2010; 85:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/27\">",
"      Herman WH, Smith PJ, Thompson TJ, et al. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 1995; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/28\">",
"      Lindstr&ouml;m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/29\">",
"      Gl&uuml;mer C, Carstensen B, Sandbaek A, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004; 27:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/30\">",
"      Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care 2008; 31:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/31\">",
"      Bang H, Edwards AM, Bomback AS, et al. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009; 151:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/32\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2312/abstract/33\">",
"      Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25:2165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1761 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-3CCE354FD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2312=[""].join("\n");
var outline_f2_16_2312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE 1 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPE 2 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arguments for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Screening tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Blood glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hemoglobin A1C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Urine glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2377257\">",
"      Effectiveness of early detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Screening recommendations by expert groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Calculating a risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      A suggested approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/3/28731\" title=\"table 1\">",
"      ADA criteria for diagnosis diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/61/2011\" title=\"table 2\">",
"      Categories of increased risk for diabetes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=related_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=related_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2313="Motivational interviewing for substance use disorders";
var content_f2_16_2313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Motivational interviewing for substance use disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Karen Ingersoll, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2313/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/16/2313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9274824\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational interviewing is a directive, patient-centered counseling approach that aims to help people change problem behaviors. Motivational interviewing is used to enhance intrinsic motivation to change by exploring and resolving ambivalence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/1\">",
"     1",
"    </a>",
"    ]. Motivational interviewing has been found to reduce substance use among individuals with substance abuse or dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic describes the theoretical foundation, indications, assessment, practice, efficacy, and administration of motivational interviewing. Brief intervention for unhealthy alcohol and other drug use, and other treatments for substance use disorders are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link\">",
"     \"Opioid intoxication in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12326091\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with substance use problems and disorders often have mixed feelings and thoughts about their smoking, drug, and alcohol use. While they may perceive some negative consequences of smoking, drinking or using drugs, they also enjoy positive experiences such as intoxication, disinhibition, socialization, and pleasure. They often remain in a conflicted or ambivalent state about changing unless their perception of these costs and benefits shifts. Understanding and resolving this ambivalence is a central goal of motivational interviewing, and is accomplished through elicitation rather than persuasion.",
"   </p>",
"   <p>",
"    Motivational interviewing is a counseling approach in which clinicians use a patient-centered stance paired with eliciting techniques to help patients explore and resolve their ambivalences about changing behaviors that are not healthy. It is characterized by a collaborative, autonomy-supporting, and evocative style in which clinicians seek to understand patients&rsquo; perspectives, while directing them toward considering changing one or more behaviors by building awareness of a discrepancy between the patient&rsquo;s current and hoped-for self, avoiding confrontation, and supporting patients&rsquo; optimism about the possibility and methods for change.",
"   </p>",
"   <p>",
"    Key processes in motivational interviewing include engagement, focusing, evoking, and planning [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinicians using motivational interviewing build rapport and engage the patient with a warm, non-judgmental attitude. They elicit the patient&rsquo;s ideas and feelings about a range of current behaviors, how these fit with hopes and values, and whether the patient can imagine better options than the current behaviors. During this process, they focus on particular changes that the patient wants to make, and match the agenda to the patient&rsquo;s priorities. The clinician elicits the patient&rsquo;s own reasons and rationale for possible changes, referred to as &ldquo;",
"    <strong>",
"     change talk",
"    </strong>",
"    &rdquo;. Once people are resolved on changing, they can often do it on their own. Thus, while not essential, motivational interviewing can include processes of planning for and activating changes. In general, motivational interviewing is focused more on discussing the &ldquo;whether&rdquo; and &ldquo;why&rdquo; to change than the &ldquo;how.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274815\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1531902\">",
"    <span class=\"h2\">",
"     Conceptual model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A conceptual model of motivational interviewing has yet to fully emerge, but components can be described. The stance of the clinician conducting motivational interviewing is collaborative, evocative, and autonomy-supporting. Clinicians maintain this stance (known as &ldquo;motivational interviewing Spirit&rdquo;) across sessions, demonstrating empathy for the patient while providing enough direction to guide the patient toward considering a change. The developing model suggests that if the clinician practicing motivational interviewing shows motivational interviewing Spirit and provides both empathy and direction, patients will show higher engagement, lower resistance, and higher change talk in motivational interviewing sessions, and should have better outcomes.",
"   </p>",
"   <p>",
"    Two active components have been proposed as leading to the efficacy of motivational interviewing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relational component that includes empathizing, collaborating, evoking patient talk about their perspectives, and supporting patient autonomy",
"     </li>",
"     <li>",
"      A technical component that includes evoking and reinforcing change talk. These components may or may not be unique to motivational interviewing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete model of motivational interviewing would elucidate elements unique to motivational interviewing and elements shared with other psychotherapies, and would demonstrate how the relational, technical, and interpersonal components influence patient changes in beliefs, perspectives, emotions, and actions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12325111\">",
"    <span class=\"h2\">",
"     Psychological theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Principles of motivational interviewing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/1,5\">",
"     1,5",
"    </a>",
"    ] are grounded in psychological theory, and in some cases, research evidence. The clinical implementation of these principles is described later in the topic. (See",
"    <a class=\"local\" href=\"#H10072449\">",
"     'Principles'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Motivational interviewing facilitates behavior change partly by accepting the patient&rsquo;s current level of readiness for change, and refraining from pushing for change that the patient is not ready for. This respectful approach is consistent with the transtheoretical model (TTM) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/6\">",
"     6",
"    </a>",
"    ], which outlines how people make deliberate changes, especially eliminating problem behaviors and beginning new, healthier behaviors. In the TTM, behavior change is seen as a process that progresses from low awareness and no intention to change, through high awareness and active efforts to initiate or maintain change. Readiness to change is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link&amp;anchor=H603354#H603354\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\", section on 'Readiness to change'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Techniques for developing discrepancy in motivational interviewing are intended to foster a different vision of the self and desired behaviors, consistent with modern emotions theory and self-determination theory (SDT) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/7\">",
"     7",
"    </a>",
"    ]. Motivational interviewing seeks to build internal motivation to change, and to elicit the person&rsquo;s propensity for positive growth, which are the central sources of motivation according to SDT. SDT suggests that motivational interviewing focuses on autonomous motivations for behaviors that lead toward desired outcomes including intrinsic rewards, extrinsic gain or increased consistency between one&rsquo;s values and identity.",
"   </p>",
"   <p>",
"    Resolving ambivalence is usually viewed as a cognitive task done to make a choice. It also has critical emotional elements that should not be overlooked. Motivation can be described as a process of opening up to new experiences while actively creating resources to support change [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Evoking a positive emotion such as interest may lead to greater openness. When patients experience interest, wonder, or curiosity, their cognitive focus broadens to consider novel options. Increased flexibility in conceptualizing situations may then facilitate resolution of ambivalence and increase openness to engage in activities that lead toward change.",
"   </p>",
"   <p>",
"    When taking action in the new direction, patients may improve certain skills and increase the likelihood of achieving a desired outcome. This increases confidence, sense of accomplishment, self-esteem and positive mood, and creates more resources for the person to use for even more profound changes.",
"   </p>",
"   <p>",
"    Rolling with resistance is supported by interpersonal theory, which has shown that a friendly style elicits reciprocal friendly responses, while a hostile style elicits a hostile response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/10\">",
"     10",
"    </a>",
"    ]. Interpersonal theory also suggests that a dominant interpersonal style pulls for submissive behavior, (or sometimes, for reciprocal dominant behavior), while submission pulls for dominant behavior. For many people in a leadership role, it is natural to default to a more dominant style. Warm dominance includes being outgoing, encouraging, praising, and suggesting, while cold dominance includes directing, warning, confronting, or disapproving.",
"   </p>",
"   <p>",
"    Studies have found reduced substance use followed verbal commitments to change [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Explanations for this relationship have been derived from several theories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Self-perception theory focuses on the patient noticing their own speech and making their behavior consistent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Implementation intentions theory emphasizes processes underlying making a commitment and taking action on it [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Social cognitive theory emphasizes both observational learning and experience as informing the development of self-efficacy and success in changing behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1022923\">",
"    <span class=\"h2\">",
"     Conceptualization of problem substance use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the context of motivational interviewing, whether or not a patient has a substance use disorder (SUD) is less relevant than the patient&rsquo;s perception that they should make some changes in their lives. Clinicians using motivational interviewing in patients with a history of substance dependence may elect to advise against drinking and drug use altogether; but, in a motivational interviewing approach, the patient&rsquo;s perspective on their addictive behaviors is more important than the clinician&rsquo;s perspective.",
"   </p>",
"   <p>",
"    Rather than conceptualizing the patient as having an SUD, he or she would be understood as being stuck in unhealthy behaviors, and thus, they can become unstuck. Unhealthy behavior patterns are seen as the result of competing motivations to make changes and to remain the same. When the benefits of changing outweigh the costs, and when remaining the same is less desirable than changing, the model suggests, people proceed with changing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274936\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for motivational interviewing include people across the continuum of substance misuse, from problem drinking or drug use to those with severe alcohol or drug dependence. Motivational interviewing has been used for varied age groups, diverse settings (including in the criminal justice system), varied substances, and associated behaviors, with varied goals.",
"   </p>",
"   <p>",
"    There are no data indicating that certain subgroups of patients with SUDs are more or less likely to benefit from motivational interviewing. A meta-analysis suggested that motivational interviewing may be more effective when clinicians and patients are not matched on the basis of racial, ethnic, or cultural characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no absolute contraindications to motivational interviewing. Patients with cognitive impairments or reduced abilities to think abstractly might have difficulty imagining the potential benefits of change or deciding among potential strategies for change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274943\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment is informal in motivational interviewing, and includes procedures such as open questions and reflective statements to develop an understanding of the patient&rsquo;s perspective and context.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reflective listening &mdash; This technique involves careful listening, followed by hypothesizing what the patient might mean, then feeding back this hypothesis to the patient in the form of a statement. As an example, if a patient says, &ldquo;I have tried to quit using drugs so many times,&rdquo; the clinician using motivational interviewing may hear this, hypothesize that the patient is discouraged, and state, &ldquo;It hasn&rsquo;t been easy to stick to your plans to quit using.&rdquo; The patient can then agree, usually signified by continuing the conversation, or may clarify if the clinician has not understood. In this way, reflective listening is iterative and self-correcting.",
"     </li>",
"     <li>",
"      Open versus closed-ended questions &mdash; Open questions are preferred in motivational interviewing because they get the patient talking. A goal in motivational interviewing is to increase patient speech while reducing clinician speech, so that the patient&rsquo;s perspective is elicited fully. As an example of an open question, a clinician using motivational interviewing might say &ldquo;Tell me about your use of alcohol and drugs.&rdquo; A clinician asking a closed question might ask &ldquo;how many times have you used alcohol or other drugs this week?&rdquo; Open questions generally evoke more responses, and specifically, open questions about the patients&rsquo; own concerns tend to evoke change talk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In conducting an initial interview, the clinician using motivational interviewing is seeking to understand the patient&rsquo;s perspective as fully as possible. This means that the clinician using motivational interviewing does not have a specific list of assessment questions or domains in mind at the start of motivational interviewing for SUD. The clinician may query content areas such as the patient&rsquo;s:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concerns and reasons for coming to the session",
"     </li>",
"     <li>",
"      Concerns about substance use patterns and benefits from the substance",
"     </li>",
"     <li>",
"      Hopes for the future, including whether the patient wants to consider reducing or ceasing substance use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many clinicians using motivational interviewing defer reviewing any formal patient assessments (eg, from other clinicians, from law enforcement authorities) until after the initial session. This allows them to focus on the patient&rsquo;s perspective during the first session rather than that of others. It can be useful to elicit the patient&rsquo;s perspective on what is likely to happen with their spouse, probation officer, boss, or others if they choose one or another behavioral path.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072937\">",
"    <span class=\"h2\">",
"     Readiness to change",
"    </span>",
"    &nbsp;&mdash;&nbsp;By remaining focused on the patient&rsquo;s concerns and ideas about change, clinicians can assess the patient&rsquo;s current readiness to change, and customize the strategies they use to the patient&rsquo;s stage of readiness. Readiness to change is discussed above and in greater detail separately (See",
"    <a class=\"local\" href=\"#H12325111\">",
"     'Psychological theory'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link&amp;anchor=H603354#H603354\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\", section on 'Readiness to change'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example of tailoring, in response to a patient who states &lsquo;I&rsquo;d like to cut back further on smoking, but the withdrawal really gets to me,&rdquo; the clinician might offer &ldquo;You have mixed feelings about quitting &mdash; you&rsquo;ve already made progress towards it, but you know that the actual giving up and the withdrawal you experience are tough.&rdquo; In this way, the clinician captures the ambivalence so common in the Contemplation stage of change.",
"   </p>",
"   <p>",
"    Patient readiness for change can fluctuate within a single discussion in the same clinical encounter. By maintaining a patient-centered perspective and eliciting patient readiness to change rather than attempting to use pressure to motivate change, the clinician using motivational interviewing can avoid evoking resistance by getting ahead of the patient. The patient then feels understood and respected, and is more willing to engage in a consideration of change. Stages of readiness to change, and their assessment, are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link&amp;anchor=H603354#H603354\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\", section on 'Readiness to change'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1022912\">",
"    <span class=\"h2\">",
"     Motivation enhancement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational enhancement therapy (MET), a four-session variant of motivational interviewing, includes structured, specific assessment of the patient&rsquo;s substance use (including quantitative assessment of consumption) and personalized risk feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to structured assessment of consumption, some forms of MET incorporate measures of the harmful effects of a patient&rsquo;s substance use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274950\">",
"    <span class=\"h1\">",
"     PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The practice of motivational interviewing has a &ldquo;quiet and eliciting&rdquo; style in which the &ldquo;therapeutic relationship is more like a partnership&hellip; than",
"    <span class=\"nowrap\">",
"     expert/recipient",
"    </span>",
"    roles&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/17\">",
"     17",
"    </a>",
"    ]. The patient has intimate knowledge of her or himself; the clinician using motivational interviewing has skill in managing a constructive conversation about change. The clinician provides direct and indirect support for the patient&rsquo;s autonomy to make choices about alcohol and drug use, which could include continued harmful use, using while reducing harms, or abstinence from using alcohol",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drugs. The clinician also supports the patient&rsquo;s ability to take actions to change substance use habits.",
"   </p>",
"   <p>",
"    Clinicians using motivational interviewing should be friendly, which elicits a cooperative stance. While motivational interviewing has a directive component, leading the patient to explore and resolve ambivalence and initiate change, this directive process is not interpersonally dominant. The clinician using motivational interviewing remains an ally of the patient, rather than of the behavior change.",
"   </p>",
"   <p>",
"    The spirit of motivational interviewing is evocative. Clinicians ask questions and reflect the patient&rsquo;s perceptions in such a way that a new understanding or commitment is evoked through the conversation. The clinician elicits the patient&rsquo;s perspective to define which behaviors are relevant to their substance use problems, explores the patient&rsquo;s own concerns about these behaviors, and elicits the patient&rsquo;s intention to change or optimism about change, which are aspects of &ldquo;change talk.&rdquo; Many motivational interviewing practitioners believe that the spirit of motivational interviewing, which reflects a unique collaboration between two experts, may be more important than specific techniques.",
"   </p>",
"   <p>",
"    Providing education about addiction concepts or persuasion may provoke resistance or reluctance. Using motivational interviewing, clinicians elicit more information than they provide. The patient does more of the talking, explaining, exploring, and considering. Clinicians using the motivational interviewing approach tend to ask rather than tell, and listen rather than advise. Clinicians using motivational interviewing show curiosity about the patient&rsquo;s use of substances rather than content expertise.",
"   </p>",
"   <p>",
"    In general, if the clinician wants to provide information, it is best to first elicit what the patient already knows, then ask permission to add a bit more information, followed by eliciting the patient&rsquo;s reaction to it. If a clinician chooses to provide advice, it is only after asking permission (ie, &ldquo;I have some suggestions for you to consider about this if you&rsquo;d like to hear them.&rdquo;).",
"   </p>",
"   <p>",
"    In learning about the patient&rsquo;s experiences and perceptions, the clinician may occasionally reframe the patient&rsquo;s perspectives to evoke interest in change. As an example, the clinician may hear a patient stating that he can &ldquo;really hold his liquor,&rdquo; and rather than providing information about tolerance, might reframe the patient&rsquo;s statement in this way: &ldquo;You&rsquo;ve noticed you can drink more than others without it affecting you as much. I&rsquo;m wondering if this might actually be a risk for you.&rdquo; Patient: &ldquo;what do you mean, risk?&rdquo; Clinician: &ldquo;It sounds like you may not have the internal sense of when you&rsquo;ve had enough. At the levels you can drink comfortably, there can be some damage to organs and tissues. Those are the risks I mean.&rdquo;",
"   </p>",
"   <p>",
"    The clinician using motivational interviewing maintains a deliberate focus on the goal of exploring and resolving ambivalence, whether the patient is choosing between abstinence and continued use, or between continued unhealthy or reduced harm use.",
"   </p>",
"   <p>",
"    Motivational interviewing practice builds upon this collaborative relationship with a basic communication style (known by the acronym OARS) that is used throughout consultation or counseling sessions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       O",
"      </strong>",
"      pen questions that encourage further elaboration and consideration",
"     </li>",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      ffirmations that foster positive feelings in the consultation",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      eflections that indicate that the clinician has heard and accurately understood the patient",
"     </li>",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      ummaries that extend the basic reflections to include a sense of momentum or build interest in changing direction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These techniques are used to build rapport and gain understanding of a patient&rsquo;s issues, to mend rifts in the treatment relationship, to redirect patients to more useful areas of consideration, and to solidify commitment to change in an established relationship where therapeutic alliance is strongly present.",
"   </p>",
"   <p>",
"    The motivational interviewing style prescribes that the clinician-patient relationship is inherently non-hierarchical and centered on the patient&rsquo;s experience. Clinicians using motivational interviewing sometimes introduce this conversation as different, as in the following example. Doctor: &ldquo;I&rsquo;d like to spend a few minutes talking about your drinking, so I can understand you better. Here I don&rsquo;t want to hear about your symptoms or problems like I might if you came in with a cold. Instead, tell me a little bit about your typical day, and how drinking fits in.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072449\">",
"    <span class=\"h2\">",
"     Principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Principles of motivational interviewing include expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The theoretical foundation for these principles is described above. (See",
"    <a class=\"local\" href=\"#H12325111\">",
"     'Psychological theory'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072456\">",
"    <span class=\"h3\">",
"     Express empathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can build rapport with patients and engage them by seeking to understand their perspective, expressing empathy with their situation, and assessing readiness to change. A clinician using motivational interviewing with a patient with a long history of opioid addiction might say: &ldquo;Your use of both heroin and prescription narcotics have brought you to a really scary place, yet you&rsquo;re here now to consider what to do about it.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072463\">",
"    <span class=\"h3\">",
"     Develop discrepancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eliciting the patient&rsquo;s perceptions of how well their current behaviors match up with their hoped-for behaviors can be a means of collaboratively identifying discrepancies between the two. As an example, the clinician might ask (taking care to avoid any sarcasm), &ldquo;Tell me more about how drinking in this pattern fits with your plans to take your education further.&rdquo; These discrepancies can illustrate negative outcomes if the patient&rsquo;s behavior does not change. They help the patient focus on a particular behavior change target, and build motivation to change it. Developing discrepancy can also result from eliciting the patient&rsquo;s perceptions of their current good qualities and how they could be expanded, and the likely positive outcomes if such a change was made.",
"   </p>",
"   <p>",
"    A clinician might say, &ldquo;So you&rsquo;ve been successful at keeping hard drugs out of your life for quite a while now. You&rsquo;re proud of what you&rsquo;ve done there. How does that apply to your cigarette smoking?&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072470\">",
"    <span class=\"h3\">",
"     Roll with resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than arguing for change (ie, confronting the patient&rsquo;s resistance), the clinician should roll with the resistance, letting the patient make the arguments for change.",
"   </p>",
"   <p>",
"    As an example, if the patient says: &ldquo;I&rsquo;m not even the one with a problem. My wife nagged me to come in, but my drinking is not an issue.&rdquo; The clinician not using motivational interviewing might end up in an argument with the patient. &ldquo;So your drinking isn&rsquo;t a problem? But your drinking is far over the limits for healthy consumption. You should not be drinking at this level.&rdquo;",
"   </p>",
"   <p>",
"    A clinician using motivational interviewing might alternatively say, &ldquo;It was important for you to soothe your wife by coming in. Still, you&rsquo;re not sure that your drinking is any kind of problem. Tell me a little bit about how drinking fits in your life.&rdquo; Once the patient begins discussing drinking, and potentially the positive effects of drinking, he may naturally present the &ldquo;other side,&rdquo; or the negative effects.",
"   </p>",
"   <p>",
"    If the patient does not offer this information, the clinician using motivational interviewing might reflect the patient&rsquo;s comments and then ask about it. &ldquo;So you really enjoy having a drink to relax after a hard work day, and it seems that having four to six beers a night is ok for you. What about the other side? Are there any downsides to your drinking, from your perspective?&rdquo;",
"   </p>",
"   <p>",
"    This approach sometimes encourages the patient to discuss conflicting or ambivalent feelings about drinking (or other substance use) but in a neutral manner in which the patient does not feel judged. Using these techniques, clinicians using motivational interviewing evoke the patient&rsquo;s ambivalence about substance use, and the discussion typically provides momentum toward resolution of ambivalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10072477\">",
"    <span class=\"h3\">",
"     Support self-efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-efficacy is the belief that one can accomplish a specific behavior. As an example, a patient may have self-efficacy that they can avoid drug use while at home, even if they are less confident that they can avoid using at a friend&rsquo;s house. The clinician should keep in mind that it is the patient&rsquo;s responsibility to decide to change, to make a plan to achieve change, and to implement the plan; the clinician&rsquo;s role is to guide and encourage these processes. A clinician using motivational interviewing may support self efficacy by reflecting it, then asking a key question, as in this example. &ldquo;So you&rsquo;ve decided you want to cut back or even eliminate using cocaine. At home, you have gotten rid of all your paraphernalia and are not planning to bring any more drugs there. So the main area that&rsquo;s still a little tempting is when you are visiting a friend and they might have some and offer it to you. What do you want to do about that temptation?&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274957\">",
"    <span class=\"h2\">",
"     Specific techniques",
"    </span>",
"   </p>",
"   <p>",
"    The flow of motivational interviewing has been characterized as involving four processes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/3\">",
"     3",
"    </a>",
"    ]: engaging, focusing, evoking, and planning. Specific techniques are applied in each process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274965\">",
"    <span class=\"h3\">",
"     Engaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engaging with the patient thoughtfully can set the stage for rapid and rewarding progress, while failing to build a relationship built on mutual respect and collaboration can result in frustration for both clinician and patient. Several procedures can contribute constructively to a patient interview, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Setting the agenda collaboratively for the conversation",
"     </li>",
"     <li>",
"      Providing information in a productive manner",
"     </li>",
"     <li>",
"      Eliciting the patient&rsquo;s strengths",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A vignette compares the engagement process using a motivational interviewing approach to a non-motivational interviewing approach (",
"    <a class=\"graphic graphic_table graphicRef87241 \" href=\"UTD.htm?42/5/43101\">",
"     table 1",
"    </a>",
"    ). In the motivational interview, the clinician uses reflective listening throughout, with open questions and affirmations to keep the conversation positive and meaningful. These techniques place the patient in the position of arguing for change (smoking cessation), and empower her to consider the options that would help her move toward change. The clinician is non-judgmental, curious, and patient-centered.",
"   </p>",
"   <p>",
"    The following steps provide a template for using OARS to facilitate the process of engagement, setting the stage for a constructive conversation about change.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What are your concerns about your [health issue]?",
"     </li>",
"     <li>",
"      Reflect what you hear.",
"     </li>",
"     <li>",
"      Affirm the patient&rsquo;s thoughts, actions, or feelings about the issue",
"     </li>",
"     <li>",
"      Tell me more. (Open questions)",
"     </li>",
"     <li>",
"      Reflect what you hear.",
"     </li>",
"     <li>",
"      Summarize the main points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274880\">",
"    <span class=\"h3\">",
"     Focusing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next process is focusing, or developing a single focus to discuss in the current conversation from among the many potential issues on a broad health agenda. Because most patients have multiple life issues, and sometimes several health issues, there are usually many possible topics on which to focus. Helping the patient to focus on one or two specific changes they could make is more likely to lead to actual change than developing a laundry list of changes that can be overwhelming.",
"   </p>",
"   <p>",
"    Clinicians using motivational interviewing help patients focus on a change they can make, typically on small steps that can succeed quickly, in order to build motivation. Once patients have some success, they are often encouraged and energized to try even bigger changes.",
"   </p>",
"   <p>",
"    A vignette compares a motivational interviewing approach to a patient to a non-motivational interviewing approach, illustrating motivational interviewing techniques for engaging the patient in behavioral change after experiencing a myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef87243 \" href=\"UTD.htm?31/27/32190\">",
"     table 2",
"    </a>",
"    ). In the motivational interview, the clinician reflects the patient&rsquo;s concerns and elicits his thoughts and feelings about what to focus on in order to get his heart healthy. Rather than the clinician advising which changes to make from among the many options, the patient selects the two behavior targets he is ready to change&mdash;drinking and exercise&mdash;and enlists the clinician&rsquo;s help and expertise in planning for success.",
"   </p>",
"   <p>",
"    The following steps provide a template for using OARS to facilitate the process of focusing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tell me about one part of this [health issue] you are most interested in changing now (Open question, narrowing agenda)",
"     </li>",
"     <li>",
"      Reflect what you hear",
"     </li>",
"     <li>",
"      Affirm the person&rsquo;s thoughts, actions, or feelings about the issue",
"     </li>",
"     <li>",
"      Explore values related to the one part (Develop discrepancy between current behavior and values) (See",
"      <a class=\"local\" href=\"#H10072463\">",
"       'Develop discrepancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reflect what you hear",
"     </li>",
"     <li>",
"      How would things be different once you&rsquo;ve made this change? What would be the best thing about making this change? (Open questions)",
"     </li>",
"     <li>",
"      Summarize the main points",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274887\">",
"    <span class=\"h3\">",
"     Evoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next process is evoking. While motivational interviewing seeks to elicit the patient&rsquo;s perspectives throughout the conversation, here evoking refers to eliciting a specific part of the patient&rsquo;s perspective&mdash;the thoughts that move them towards change. Statements of reasons to change, ability to change, need to change, desire to change, steps already taken toward change, and commitment to change are considered &ldquo;Change Talk.&rdquo;",
"   </p>",
"   <p>",
"    During the process of evoking, the clinician seeks to understand the patient&rsquo;s thoughts and feelings consistent with healthy change. As an example, the patient says, &ldquo;I&rsquo;d like to quit smoking soon.&rdquo; The clinician replies, &ldquo;What are some of your reasons for wanting to quit? How might you go about it?&rdquo;",
"   </p>",
"   <p>",
"    In a vignette (",
"    <a class=\"graphic graphic_table graphicRef87244 \" href=\"UTD.htm?14/18/14636\">",
"     table 3",
"    </a>",
"    ), the clinician using motivational interviewing employs scaling rulers and key questions to evoke change talk. Scaling rulers are a technique designed to elicit a numeric value (&ldquo;on a scale of 0 to 5, with 5 as the highest&rdquo;) for importance, confidence, or readiness, followed by a question such as &ldquo;what makes it a 5 and not a 0?&rdquo; A patient cannot answer that follow-up question without providing some level of change talk. Key questions are questions with momentum built in, such as in the template below (ie, &ldquo;Where does this leave you? What&rsquo;s the next step?&rdquo;). When the patient expresses change talk, the clinician should reflect or restate it back to the patient as a way of underlining its importance. These steps can help solidify patient&rsquo;s motivation to make changes, and prepare him or her for the planning process.",
"   </p>",
"   <p>",
"    The following steps provide a template for using OARS to evoke change talk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tell me about why this change would be good for you (Open question)",
"     </li>",
"     <li>",
"      Reflect what you hear",
"     </li>",
"     <li>",
"      What makes this change important to you? What might happen if you don&rsquo;t make this change? (Open questions)",
"     </li>",
"     <li>",
"      Affirm the patient&rsquo;s motivations, and reflect the patient&rsquo;s vision for the future (Affirmation and Summary)",
"     </li>",
"     <li>",
"      Where does this leave you? What&rsquo;s the next step? (Open questions)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274894\">",
"    <span class=\"h3\">",
"     Planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The last process in a motivational interviewing conversation (or series of conversations) is planning. While formal change planning may not always be part of motivational interviewing, most motivational interviewing conversations contain at least conceptual aspects, and maybe some practical aspects, of planning to change. Planning includes exploring specific barriers to and facilitators of change, and is essentially a problem solving process in which the patient considers how to make changes, how to deal with challenges, and how to measure success. A vignette (",
"    <a class=\"graphic graphic_table graphicRef87245 \" href=\"UTD.htm?35/48/36621\">",
"     table 4",
"    </a>",
"    ) illustrates a motivational interviewing-consistent example of the planning process.",
"   </p>",
"   <p>",
"    The clinician begins the planning process with a summary of their conversation to date, which includes a mention of a past success. Helping patients to recall past successes can stoke their fire for change. Instead of evoking &ldquo;reasons,&rdquo; change talk, the clinician evokes commitment using a 0 to 5 scale to assess the patient&rsquo;s confidence in making the change. Using reflections and short summaries, the clinician supports the patient&rsquo;s autonomy and plan for change, and offers support if needed.",
"   </p>",
"   <p>",
"    The following steps provide a template for using OARS to develop a change plan:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the change you want to make?",
"     </li>",
"     <li>",
"      What are the important reasons to make this change now?",
"     </li>",
"     <li>",
"      What&rsquo;s the first step? What else?",
"     </li>",
"     <li>",
"      Who could help you?",
"     </li>",
"     <li>",
"      What might get in the way?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9274972\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 meta-analysis of 59 randomized trials with a total of 13,342 adult participants with substance abuse or dependence found that, compared to no treatment, motivational interviewing resulted in a significant reduction in substance use post-intervention (standardized mean difference [SMD]=0.79, 95% CI 0.48-1.09) and at subsequent follow up for as long as 12 months (SMD=0.15, 95% CI 0.04-0.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/2\">",
"     2",
"    </a>",
"    ]. No difference in substance use was seen when motivational interviewing was compared to treatment as usual for SUDs, other active treatments, and receiving substance abuse assessment and feedback. The meta-analysis was limited to trials that reviewed audio or videotapes of treatment sessions to assess fidelity to the motivational interviewing model. Trials were noted to be of low to moderate quality.",
"   </p>",
"   <p>",
"    As an example, a trial of 461 patients with substance abuse and dependence randomly compared a four-week structured motivational interviewing intervention with counseling as usual [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/18\">",
"     18",
"    </a>",
"    ]. Motivational interviewing led to reductions in use compared to counseling as usual that were sustained subsequently over 12 weeks. There was no difference between groups in the percentage of urine samples positive for substances.",
"   </p>",
"   <p>",
"    Few trials have been conducted comparing the combination of motivational interviewing and a SUD treatment intervention to the intervention alone, but initial results are promising. A randomized trial of 105 outpatients with cocaine dependence compared detoxification and a motivational interviewing intervention to detoxification alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients who received the motivational interviewing intervention increased their use of behavioral coping strategies and had fewer urine samples positive for cocaine at the start of subsequent treatment.",
"   </p>",
"   <p>",
"    Other systematic reviews and meta-analyses have found motivational interviewing to be effective in treating substance abuse in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/20\">",
"     20",
"    </a>",
"    ] and college students [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/21\">",
"     21",
"    </a>",
"    ], and in smoking cessation (which was excluded from the 2011 meta-analysis above) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/22\">",
"     22",
"    </a>",
"    ]. Additional findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With training, motivational interviewing can be delivered effectively by physicians, counselors, and other staff; professional role does not appear to affect the efficacy of motivational interviewing [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Motivational interviewing typically achieves its effects in one to four sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/23\">",
"       23",
"      </a>",
"      ]. Motivational interviewing appears to require a &ldquo;minimum dose&rdquo; of about 20 minutes. More sessions have been associated with greater efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H538672\">",
"    <span class=\"h2\">",
"     Mechanisms of improvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review article analyzing the association between therapist behaviors, patient behaviors, and subsequent patient outcomes in 19 controlled trials of motivational interviewing found three motivational interviewing constructs to be associated with patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient change talk or intention language are related to better outcomes",
"     </li>",
"     <li>",
"      Patient perceptions of discrepancy are related to better outcomes",
"     </li>",
"     <li>",
"      Motivational interviewing-inconsistent behaviors, such as providing advice without permission or warning, are related to worse outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10073078\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motivational interviewing is generally provided in one to four sessions of 15 to 45 minute duration. A minimum duration of 20 minutes appears to be needed, with greater efficacy associated with more sessions. (See",
"    <a class=\"local\" href=\"#H9274972\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10073047\">",
"    <span class=\"h1\">",
"     TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like many other clinical skills, motivational interviewing requires time and practice to learn to do well. A systematic review of training methods in motivational interviewing (MI) found that while most methods promoted MI skills, those using an objective system of evaluation and feedback (coding and coaching) promoted broader, deeper learning with persistent effects on practitioner skills [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/25\">",
"     25",
"    </a>",
"    ]. Studies suggest that for many practitioners, motivational interviewing skills development can be effectively facilitated through [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reviewing motivational interviewing concepts either by reading or participating in a workshop",
"     </li>",
"     <li>",
"      Followed by practicing motivational interviewing skills",
"     </li>",
"     <li>",
"      Subsequent clinical supervision and coaching",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies of training medical practitioners have found that the use of web-based learning, standardized patients, workshop-based learning, and clinical supervision can all foster learning of MI skills [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/28-34\">",
"     28-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A website administered by the non-profit Motivational Interviewing Network of Trainers (MINT) provides an international listing of trainers experienced in training medical personnel to use motivational interviewing (",
"    <a class=\"external\" href=\"file://www.motivationalinterviewing.org/\">",
"     file://www.motivationalinterviewing.org",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Information is also available in book form on using motivational interviewing in health care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/35\">",
"     35",
"    </a>",
"    ] and on the development of specific motivational interviewing skills [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539034\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Motivational interviewing is a directive, patient-centered approach that aims to help people change problem behaviors. Motivational interviewing is used to enhance intrinsic motivation to change by exploring and resolving ambivalence. (See",
"      <a class=\"local\" href=\"#H9274824\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidates for motivational interviewing include people across the continuum of substance misuse, from problem drinking or drug use to those with severe alcohol or drug dependence. Motivational interviewing has been used for varied age groups, in diverse settings (including primary care, specialty care, and the criminal justice system), and for abuse of or dependence on varied substances. (See",
"      <a class=\"local\" href=\"#H9274936\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basic communication style in motivational interviewing (known by the acronym OARS) is composed of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       O",
"      </strong>",
"      pen questions that encourage further elaboration and consideration.",
"     </li>",
"     <li>",
"      <strong>",
"       A",
"      </strong>",
"      ffirmations that foster positive feelings in the consultation.",
"     </li>",
"     <li>",
"      <strong>",
"       R",
"      </strong>",
"      eflections that indicate that the clinician has heard and accurately understood the patient.",
"     </li>",
"     <li>",
"      <strong>",
"       S",
"      </strong>",
"      ummaries that extend the basic reflections to include a sense of momentum or build interest in changing direction. (See",
"      <a class=\"local\" href=\"#H9274950\">",
"       'Practice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Principles of motivational interviewing include expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. (See",
"      <a class=\"local\" href=\"#H10072449\">",
"       'Principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The flow of motivational interviewing involves four processes: engaging, focusing, evoking, and planning. Specific techniques are illustrated for each phase. (See",
"      <a class=\"local\" href=\"#H9274957\">",
"       'Specific techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with substance abuse or dependence, we suggest management that includes motivational interviewing, either as monotherapy or in combination with other interventions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9274972\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Motivational interviewing is generally provided in one to four sessions of 15 to 45 minute duration. A minimum duration of 20 minutes appears to be needed, with greater efficacy associated with more sessions. (See",
"      <a class=\"local\" href=\"#H10073078\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our experience, the best development of motivational interviewing skills occurs through participation in a workshop that includes reviewing motivational interviewing concepts, practicing motivational interviewing skills, and coaching. Information is also available in book form on using motivational interviewing in health care [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/35\">",
"       35",
"      </a>",
"      ] and on the development of specific motivational interviewing skills [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2313/abstract/36\">",
"       36",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10073047\">",
"       'Training'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change, 2nd ed., Guilford Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/2\">",
"      Smedslund G, Berg RC, Hammerstr&oslash;m KT, et al. Motivational interviewing for substance abuse. Cochrane Database Syst Rev 2011; :CD008063.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WR, Rollnick S. Motivational Interviewing, Guilford Press, New York 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/4\">",
"      Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol 2009; 64:527.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior, 1st ed., Guilford Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/6\">",
"      Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997; 12:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/7\">",
"      Markland D, Ryan RM, Tobin V, Rollnick S. Motivational interviewing and self-determination theory. J Soc Clin Psychol 2005; :785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/8\">",
"      Fredrickson BL. The broaden-and-build theory of positive emotions. Philos Trans R Soc Lond B Biol Sci 2004; 359:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/9\">",
"      Fredrickson BL, Losada MF. Positive affect and the complex dynamics of human flourishing. Am Psychol 2005; 60:678.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WR, Zweben A, DiClemente CC, et al. Motivational Enhancement Therapy Manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence, NIAAA/NIH, Rockville, MD 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/11\">",
"      Marlatt GA, Curry S, Gordon JR. A longitudinal analysis of unaided smoking cessation. J Consult Clin Psychol 1988; 56:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/12\">",
"      Amrhein PC, Miller WR, Yahne CE, et al. Client commitment language during motivational interviewing predicts drug use outcomes. J Consult Clin Psychol 2003; 71:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/13\">",
"      Bem DJ. Self-perception: An alternative interpretation of cognitive dissonance phenomena. Psychol Rev 1967; 74:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/14\">",
"      Gollwitzer PM, Sheeran P. Implementation intentions and goal achievement: A meta-analysis of effects and processes. Adv Exp Soc Psychol 2006; :69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/15\">",
"      Bandura A. Human agency in social cognitive theory. Am Psychol 1989; 44:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/16\">",
"      Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol 2005; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/17\">",
"      Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother 1995; :325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/18\">",
"      Ball SA, Martino S, Nich C, et al. Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol 2007; 75:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/19\">",
"      Stotts AL, Schmitz JM, Rhoades HM, Grabowski J. Motivational interviewing with cocaine-dependent patients: a pilot study. J Consult Clin Psychol 2001; 69:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/20\">",
"      Tait RJ, Hulse GK. A systematic review of the effectiveness of brief interventions with substance using adolescents by type of drug. Drug Alcohol Rev 2003; 22:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/21\">",
"      Carey KB, Scott-Sheldon LA, Carey MP, DeMartini KS. Individual-level interventions to reduce college student drinking: a meta-analytic review. Addict Behav 2007; 32:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/22\">",
"      Lai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010; :CD006936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/23\">",
"      Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract 2005; 55:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/24\">",
"      Apodaca TR, Longabaugh R. Mechanisms of change in motivational interviewing: a review and preliminary evaluation of the evidence. Addiction 2009; 104:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/25\">",
"      Madson MB, Loignon AC, Lane C. Training in motivational interviewing: a systematic review. J Subst Abuse Treat 2009; 36:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/26\">",
"      S&ouml;derlund LL, Madson MB, Rubak S, Nilsen P. A systematic review of motivational interviewing training for general health care practitioners. Patient Educ Couns 2011; 84:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/27\">",
"      Martino S, Canning-Ball M, Carroll KM, Rounsaville BJ. A criterion-based stepwise approach for training counselors in motivational interviewing. J Subst Abuse Treat 2011; 40:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/28\">",
"      Abramowitz SA, Flattery D, Franses K, Berry L. Linking a motivational interviewing curriculum to the chronic care model. J Gen Intern Med 2010; 25 Suppl 4:S620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/29\">",
"      Knight KM, Parr M, Walker D, Shalhoub J. Web-based training package for HEEADSSS assessment and motivational interviewing techniques: a multi-professional evaluation survey. Med Teach 2010; 32:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/30\">",
"      Roman B, Borges N, Morrison AK. Teaching motivational interviewing skills to third-year psychiatry clerkship students. Acad Psychiatry 2011; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/31\">",
"      Cucciare MA, Ketroser N, Wilbourne P, et al. Teaching motivational interviewing to primary care staff in the Veterans Health Administration. J Gen Intern Med 2012; 27:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/32\">",
"      Daeppen JB, Fortini C, Bertholet N, et al. Training medical students to conduct motivational interviewing: a randomized controlled trial. Patient Educ Couns 2012; 87:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/33\">",
"      Triana AC, Olson MM, Trevino DB. A new paradigm for teaching behavior change: implications for residency training in family medicine and psychiatry. BMC Med Educ 2012; 12:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2313/abstract/34\">",
"      Haeseler F, Fortin AH 6th, Pfeiffer C, et al. Assessment of a motivational interviewing curriculum for year 3 medical students using a standardized patient case. Patient Educ Couns 2011; 84:27.",
"     </a>",
"    </li>",
"    <li>",
"     Rollnick, S, Miller, WR, Butler, CC. Motivational interviewing in health care: helping patients change behavior., The Guilford Press, New York 2008.",
"    </li>",
"    <li>",
"     Rosengren DB. Building Motivational Interviewing Skills: A Practitioner Workbook, Guilford Press, New York 2009.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16752 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2313=[""].join("\n");
var outline_f2_16_2313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274824\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12326091\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274815\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1531902\">",
"      Conceptual model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12325111\">",
"      Psychological theory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1022923\">",
"      Conceptualization of problem substance use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274936\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274943\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10072937\">",
"      Readiness to change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1022912\">",
"      Motivation enhancement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274950\">",
"      PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10072449\">",
"      Principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072456\">",
"      - Express empathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072463\">",
"      - Develop discrepancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072470\">",
"      - Roll with resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10072477\">",
"      - Support self-efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9274957\">",
"      Specific techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9274965\">",
"      - Engaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9274880\">",
"      - Focusing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9274887\">",
"      - Evoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9274894\">",
"      - Planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274972\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H538672\">",
"      Mechanisms of improvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10073078\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10073047\">",
"      TRAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539034\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16752\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16752|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/5/43101\" title=\"table 1\">",
"      Motivational interviewing technique - Engaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/27/32190\" title=\"table 2\">",
"      Motivational interviewing technique - Focusing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/18/14636\" title=\"table 3\">",
"      Motivational interviewing technique - Evoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/48/36621\" title=\"table 4\">",
"      Motivational interviewing technique - Planning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2314="Sleep disorders in end-stage renal disease";
var content_f2_16_2314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep disorders in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Patrick J Hanly, MD, FRCPC, MRCPI,  DABSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Andreas Pierratos, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Istvan Mucsi, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Marta Novak, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/16/2314/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/16/2314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26619091\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disorders are common in patients with end-stage renal disease (ESRD). A systematic review of 17 studies in patients with ESRD indicated that &ldquo;sleep disturbance&rdquo; was one of their most common symptoms with a mean prevalence of 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/1\">",
"     1",
"    </a>",
"    ]. Sleep disorders tend to be under recognized by renal healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews sleep disorders among ESRD patients, including insomnia, excessive sleepiness, sleep apnea, restless legs syndrome (RLS), and periodic limb movement (PLM) disorder. Sleep disorders in the general population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"     \"Classification of sleep disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2600?source=see_link\">",
"     \"Approach to the patient with excessive daytime sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619098\">",
"    <span class=\"h1\">",
"     INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of insomnia among ESRD patients treated with conventional hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) ranges from 19 to 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/3-14\">",
"     3-14",
"    </a>",
"    ]. Insomnia is a significant source of stress [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/5,15\">",
"     5,15",
"    </a>",
"    ], and has been associated with increased mortality among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. The mechanism by which insomnia increases mortality among such patients is not clear but may be via an increase in systemic inflammation which has been associated with both ESRD and with poor cardiovascular outcomes among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H271949745\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contributors to insomnia include restless leg syndrome (RLS), periodic limb movement (PLM), sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/19-21\">",
"     19-21",
"    </a>",
"    ], metabolic factors including uremia, anemia, hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], bone pain and pruritus, anxiety and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], circadian rhythm disorders such as delayed sleep phase syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/4,26\">",
"     4,26",
"    </a>",
"    ], and the use of medications that prevent sleep and poor sleep hygiene, including frequent napping during daytime dialysis.",
"   </p>",
"   <p>",
"    Elevated plasma levels of orexin (a neuropeptide that promotes wakefulness) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/27\">",
"     27",
"    </a>",
"    ] and systemic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], may also contribute to poor sleep among ESRD patients. Some studies have suggested that the timing of the dialysis shift alters the severity of insomnia, such that insomnia is worse among patients who are dialyzed in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/6,28\">",
"     6,28",
"    </a>",
"    ], but this has not been shown in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619126\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients complain of difficulty initiating and maintaining sleep and early morning awakening. In addition to subjective sleep complaints, there is objective evidence of both sleep loss and sleep disruption among ESRD patients who are treated with conventional hemodialysis (defined by three times weekly in-center hemodialysis). Polysomnographic studies have reported lower than normal total sleep time (4.4 to 6 hours per night) fragmented by a high frequency of arousals (up to",
"    <span class=\"nowrap\">",
"     30/hour),",
"    </span>",
"    resulting in low sleep efficiency among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20,30,31\">",
"     20,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study that compared ESRD patients treated with conventional hemodialysis with otherwise matched non-ESRD controls, ESRD patients were more likely to have short sleep (odds ratio [OR] 3.27, 95% CI, 1.16-9.25) and less efficient sleep (OR 5.5, 95% CI 1.5-19.6), even after adjustment for cardiovascular disease, diabetes and known sleep apnea [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/32\">",
"     32",
"    </a>",
"    ]. Sleep architecture varies between studies but, generally, stages 1 and 2 non-rapid eye movement (NREM) sleep are increased whereas slow wave sleep and REM sleep are reduced among patients on hemodialysis compared with the non-ESRD population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619140\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of insomnia is not different among ESRD patients than in the general population and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619147\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of insomnia among ESRD patients is generally the same as in the non-ESRD population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, an important component of treatment that is specific to ESRD patients is the optimization of renal replacement therapy.",
"   </p>",
"   <p>",
"    The benefit of renal replacement therapy in insomnia has been evaluated in a few studies. In one retrospective study that utilized a 10-symptom questionnaire called the Pittsburgh Symptom Score to assess uremic symptoms among 45 patients, symptoms including &ldquo;trouble sleeping&rdquo; and &ldquo;restless legs&rdquo; improved nine months after the initiation of CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal modality of renal replacement therapy for the treatment of insomnia among ESRD patients is not clear. A single randomized multicenter study compared the effect of automated peritoneal dialysis (APD) with chronic ambulatory peritoneal dialysis (CAPD) on subjectively described sleep quality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/34\">",
"     34",
"    </a>",
"    ]. Among 25 patients who completed the study, 13 were allocated to CAPD and 12 to APD. APD consisted of nightly intermittent peritoneal dialysis supplemented by additional daytime manual exchanges, if required, to meet a minimum dialysis target. Both groups achieved the same mean weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    (of approximately 2.3) over a six month period. There was no difference in sleep quality at baseline or at six months.",
"   </p>",
"   <p>",
"    Nocturnal hemodialysis improves sleep apnea, but has the potential to cause sleep disruption for other reasons. This was suggested by one study that included 14 patients who were switched from conventional hemodialysis to nocturnal hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ]. Although all patients had improved sleep apnea there was no improvement in polysomnographic features of sleep fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ]. One reason for the persistent sleep disruption observed in this study is that the reduction in respiratory arousals, associated with improvement of sleep apnea, was replaced by an increase in spontaneous arousals and in arousals associated with PLM [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Experience from clinical practice has also suggested that home dialysis has the potential to disrupt sleep in some patients, most often due to technical difficulties with the mode of dialysis (eg, alarms or discomfort due to body or arm positions), as well as to anxiety about receiving dialysis during the night.",
"   </p>",
"   <p>",
"    The effect of renal transplantation on sleep quality has been evaluated in a few studies. Among 115 transplant recipients, poor sleep, assessed by the Pittsburgh Sleep Quality Index, was reported in 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/35\">",
"     35",
"    </a>",
"    ]. However it is not known whether transplantation (which was performed at least six months prior to the study) caused any change in sleep quality since a baseline assessment prior to transplantation was not obtained.",
"   </p>",
"   <p>",
"    However another study which assessed insomnia with the Athens Insomnia Scale reported a lower prevalence of insomnia (8 percent) among kidney transplant recipients compared with waitlisted dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619154\">",
"    <span class=\"h1\">",
"     EXCESSIVE SLEEPINESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive sleepiness is defined as the inability to stay awake or alert during the major waking episodes of the day, resulting in unintended lapses into drowsiness or sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37\">",
"     37",
"    </a>",
"    ]. Subjective daytime sleepiness is commonly reported among ESRD patients who are treated with conventional hemodialysis or CAPD. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 54 outpatient hemodialysis patients, daytime sleepiness was the most frequent complaint (67 percent of patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/4\">",
"       4",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In another study of 24 unselected hemodialysis patients, daytime sleepiness assessed subjectively by the Epworth Sleepiness Scale (ESS) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/38\">",
"       38",
"      </a>",
"      ] was reported in 50 percent of patients and objective sleepiness assessed by the multiple sleep latency test (MSLT) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/39\">",
"       39",
"      </a>",
"      ] was found in 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one study, among 46 hemodialysis patients who had no known cause of daytime sleepiness (such as chronic medical disorders associated with sleep disruption, central nervous system medications,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a history suggestive of sleep disorders), 50 percent of patients had sleep apnea and 50 percent had PLM [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/31\">",
"       31",
"      </a>",
"      ]. Thirteen percent of patients had evidence of &ldquo;pathological&rdquo; sleepiness, and 33 percent had mild daytime sleepiness. In addition, 48 percent of patients had REM sleep on at least one nap, and 17 percent of patients had REM sleep on two or more naps. REM sleep generally does not occur during daytime naps in a healthy well rested individual. REM sleep can occur during daytime naps due to sleep deprivation, sleep disruption, circadian rhythm disorder, narcolepsy and withdrawal from REM sleep suppressant medication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link&amp;anchor=H3#H3\">",
"       \"Stages and architecture of normal sleep\", section on 'Rapid eye movement (REM) sleep'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In this study, the high prevalence of REM sleep during daytime naps may have reflected the severity of nighttime sleep disruption or alternatively may indicate a basic desynchronization of the timing of REM sleep.",
"     </li>",
"     <li>",
"      In a survey of 201 CAPD patients, sleepiness was the most frequent sleep-related complaint (77 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 81 CAPD patients, 52 percent reported involuntary sleepiness [",
"      <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/40\">",
"       40",
"      </a>",
"      ]. Among 18 patients who had further evaluation with overnight polysomnography and MSLT, 11 (61 percent) had sleep apnea. Sleep latency was lower among patients with apnea compared with those without apnea (5.5 versus 7.7, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619168\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple ESRD-related factors contribute to sleepiness. Such factors include uremia, high prevalence of periodic limb movements (PLM) and the high prevalence of sleep apnea. In the study cited above, analysis of the MSLT data indicated that sleepiness was associated with both a higher BUN and a higher frequency of PLM, suggesting that uremia and sleep disruption associated with PLM contribute to the pathogenesis of sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep apnea contributes to daytime sleepiness among ESRD patients. In one study cited above, objective sleepiness correlated with the severity of sleep apnea and the frequency of arousals on the overnight polysomnogram [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/31\">",
"     31",
"    </a>",
"    ]. However, although mild sleep apnea was present in some patients, the respiratory disturbance index, which is a measure of apnea frequency, accounted for only 11 percent of the variability in the measures of sleepiness, which suggested that non-respiratory factors may contribute to sleepiness.",
"   </p>",
"   <p>",
"    Other contributors to daytime sleepiness may include sub-clinical uremic encephalopathy, deficiency of tyrosine which is an important precursor in the metabolism of dopamine, release of sleep inducing inflammatory cytokines during dialysis, persistence of melatonin during the daytime, and alteration of body temperature rhythm, which is closely associated with the sleep-wakefulness rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/31,41\">",
"     31,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619175\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive daytime sleepiness is manifested by falling asleep involuntarily in either passive (eg, reading, watching TV) or active (eg, driving, during conversation) situations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2600?source=see_link&amp;anchor=H362471#H362471\">",
"     \"Approach to the patient with excessive daytime sleepiness\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased daytime sleepiness may lead to decreased productivity at work or even to an increased risk of motor vehicle accidents. Its potential clinical significance varies depending on each individual patient&rsquo;s circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=see_link\">",
"     \"Performance and safety risks of sleep deprivation and sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619189\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of sleepiness among ESRD patients is the same as in the general population and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2600?source=see_link\">",
"     \"Approach to the patient with excessive daytime sleepiness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619196\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of excessive sleepiness is generally not different among ESRD patients as in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=see_link\">",
"     \"Treatment of narcolepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, among ESRD patients, the modality of renal replacement therapy may influence daytime sleepiness. Nocturnal hemodialysis may have a beneficial effect on daytime sleepiness. This was suggested by one study in which 15 ESRD patients were assessed by overnight polysomnography and MSLT before and after they were converted from conventional to nocturnal hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/30\">",
"     30",
"    </a>",
"    ]. Prior to conversion of their dialysis treatment, patients were categorized, into a somnolent group and an alert group based on the results of an MSLT. In the somnolent group, there was a trend for the frequency of PLM to fall and a corresponding trend for sleep latency to increase, whereas in the alert group, there was a trend for the frequency of PLM to increase and a corresponding trend for sleep latency to fall. When the data from these two groups were combined, a significant correlation was found between the change in PLM and the change in sleep latency. These data suggest that sleepiness may improve following conversion to nocturnal hemodialysis, possibly related to reduced sleep disruption associated with PLM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227629\">",
"    <span class=\"h1\">",
"     SLEEP APNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea is a chronic medical disorder in which patients stop breathing during sleep. There are two types of sleep apnea, both of which are found in patients with ESRD. Obstructive sleep apnea (OSA) occurs due to intermittent closure of the upper airway during sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central sleep apnea (CSA) occurs due to intermittent loss of respiratory drive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term &ldquo;mixed apnea&rdquo; is used by polysomnographic technologists when they score apneas that start as a central event and finish as an obstructive one. It is not a distinct clinical entity, nor should it be confused with patients who have both OSA and CSA that occur separately on the same sleep study.",
"   </p>",
"   <p>",
"    The severity of sleep apnea is defined by the apnea-hypopnea index (AHI) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/42\">",
"     42",
"    </a>",
"    ]. The AHI is calculated from a sleep study and describes the frequency of apneas (complete absence of airflow for 10 seconds or more) and hypopneas (partial reduction in airflow for 10 seconds or more) per hour of sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Untreated sleep apnea has many potential clinical consequences among patients with ESRD. Sleep apnea may exacerbate the symptoms of chronic kidney disease, such as daytime fatigue, sleepiness and impaired neurocognitive function which could impair health-related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, sleep apnea may exacerbate the cardiovascular complications of ESRD, which are the leading causes of morbidity and mortality among such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/44\">",
"     44",
"    </a>",
"    ]. In patients with normal renal function, OSA independently increases the prevalence of systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/45\">",
"     45",
"    </a>",
"    ], coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/46\">",
"     46",
"    </a>",
"    ]",
"    <sup>",
"    </sup>",
"    and cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/47\">",
"     47",
"    </a>",
"    ], and also exacerbates myocardial ischemia in patients with coexisting coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obstructive sleep apnea has been identified as a source of increased oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/49\">",
"     49",
"    </a>",
"    ] and systemic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/50\">",
"     50",
"    </a>",
"    ], which may accelerate the development of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/51\">",
"     51",
"    </a>",
"    ]. Among patients with ESRD, hypoxemia during sleep is associated with nocturnal hypertension, left ventricular hypertrophy, impaired sympathovagal balance and an increased risk of cardiovascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sleep apnea may increase the risk of death among ESRD patients (",
"    <a class=\"graphic graphic_figure graphicRef87179 \" href=\"UTD.htm?17/57/18335\">",
"     figure 1",
"    </a>",
"    ). One prospective cohort study of 93 CAPD patients showed an association between sleep apnea and increased all-cause mortality that was independent of age, male gender and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/56\">",
"     56",
"    </a>",
"    ]. However, this association was not observed in another study of 29 ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227644\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea is more common among ESRD patients than in the general population. The reported prevalence of sleep apnea is over 50 percent among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/40,58-60\">",
"     40,58-60",
"    </a>",
"    ], which is higher than that reported in the general population (2 to 20 percent, depending upon defining criteria) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Epidemiology'",
"    </a>",
"    ). Perhaps the best comparative data are provided by a study that compared 46 hemodialysis patients with 137 patients with normal renal function who were matched for age, gender, body mass index, and race [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/60\">",
"     60",
"    </a>",
"    ]. Hemodialysis patients were more likely to have severe sleep apnea, as defined by the apnea-hypopnea index (AHI) (OR 4.07, 95% CI 1.83-9.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of sleep apnea is similar among ESRD patients who are treated with peritoneal dialysis or hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This suggests that the pathophysiology of sleep apnea in this population is related to kidney failure itself rather than the dialysis-related factors.",
"   </p>",
"   <p>",
"    The prevalence and severity of sleep apnea is not altered by the temporal relationship to the patients&rsquo; last dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20,61\">",
"     20,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESRD patients more commonly have obstructive rather than central sleep apnea, although central sleep apnea and mixed apnea are also more commonly observed among ESRD patients than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227651\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definite risk factors for obstructive sleep apnea in the general population include obesity, craniofacial abnormalities, and upper airway soft tissue abnormalities. Potential risk factors include heredity, smoking, nasal congestion, diabetes, age, and gender [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H9969828#H9969828\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some investigators have identified similar risk factors among patients with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. However others have reported that these associations are weak in the ESRD population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/40,58,69-71\">",
"     40,58,69-71",
"    </a>",
"    ]. In a study that compared 76 hemodialysis patients with an AHI-matched, non-ESRD control group, the age and gender distribution were similar between groups, ESRD patients were generally not obese, and the BMI of ESRD patients was significantly lower than those with normal renal function (approximately 28 versus 33",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227658\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of obstructive and central sleep apnea is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues that pertain to the ESRD population are discussed here. The observation of both obstructive and central sleep apnea in ESRD patients supports the hypothesis that the pathogenesis of sleep apnea among ESRD patients is due both to destabilization of central ventilatory control and upper airway occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20,69,72\">",
"     20,69,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enhanced ventilatory sensitivity to hypercapnia that correlates with apnea severity has been reported in ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/69\">",
"     69",
"    </a>",
"    ]. Enhanced ventilatory sensitivity to hypercapnia destabilizes respiratory control by increasing a phenomenon known as loop gain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .) A reduction in ventilatory sensitivity to hypercapnia has been demonstrated among ESRD patients whose apnea improved when they were switched from conventional to nocturnal hemodialysis (",
"    <a class=\"graphic graphic_figure graphicRef87084 \" href=\"UTD.htm?20/2/20526\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/75\">",
"     75",
"    </a>",
"    ]. Among such patients, the reduction in ventilatory sensitivity correlated with a reduction in apnea severity as reflected by a fall in AHI.",
"   </p>",
"   <p>",
"    Alternatively, patients with ESRD may develop sleep apnea through mechanisms that promote upper airway occlusion during sleep. Such patients are vulnerable to fluid overload, which could contribute to pharyngeal narrowing by causing interstitial edema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased fluid volume in the neck and peripharyngeal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/76\">",
"     76",
"    </a>",
"    ]. In healthy subjects, displacement of fluid from the lower limbs has been reported to increase neck circumference and pharyngeal resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/77\">",
"     77",
"    </a>",
"    ] and reduce upper airway cross-sectional area [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/78\">",
"     78",
"    </a>",
"    ]. This mechanism has been reported to contribute to the pathogenesis of OSA in patients with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/79\">",
"     79",
"    </a>",
"    ] and in patients with congestive heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have suggested that a similar mechanism is operative among patients with ESRD. As an example, pharyngeal cross-sectional area was measured with acoustic pharyngometry in 44 hemodialysis patients and compared with a control group with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/81\">",
"     81",
"    </a>",
"    ]. Pharyngeal area was smaller among the hemodialysis patients, suggesting that such patients may be predisposed to upper airway occlusion during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/81\">",
"     81",
"    </a>",
"    ]. Furthermore, conversion of ESRD patients from conventional hemodialysis to nocturnal hemodialysis was associated with an increase in pharyngeal cross-sectional area [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/82\">",
"     82",
"    </a>",
"    ], possibly due to improved fluid removal. Conversion from continuous ambulatory peritoneal dialysis (CAPD) to nocturnal peritoneal dialysis has also been shown to reduce the frequency of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/83\">",
"     83",
"    </a>",
"    ]. The decreased prevalence of OSA among nocturnal PD patients was associated with better fluid clearance and reduced pharyngeal narrowing as measured by magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H258227686\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another potential cause of pharyngeal narrowing is upper airway dilator muscle dysfunction due to neuropathy or myopathy associated with chronic uremia or the underlying cause of ESRD, such as diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/61\">",
"     61",
"    </a>",
"    ]. Both sensory neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/85\">",
"     85",
"    </a>",
"    ] and muscle denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/86\">",
"     86",
"    </a>",
"    ] have been demonstrated in the upper airway in OSA patients with normal renal function and may exacerbate the disease process in ESRD patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227665\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the general population, common signs and symptoms of obstructive sleep apnea include loud snoring, witnessed episodes of apnea, morning headaches, and sleepiness or poor concentration during the day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H13336404#H13336404\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with ESRD may be less likely to report loud snoring, witnessed apneic episodes, and morning headaches [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/62\">",
"     62",
"    </a>",
"    ]. In addition, other symptoms, such as fatigue and sleepiness are often attributed to kidney failure. As a result, a high index of suspicion and objective monitoring may be required to make a diagnosis of sleep apnea in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227679\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of sleep apnea is difficult among ESRD patients since the characteristic clinical features of sleep apnea may be absent and since sleep-related symptoms such as fatigue and sleepiness may be attributed to kidney failure. However, the evaluation of patients with possible sleep apnea is the same among ESRD patients as in the general population and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H258227686\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat sleep apnea for the reduction of cardiovascular risk should be individualized for each patient. Although sleep apnea has been associated with increased cardiovascular risk and with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/55\">",
"     55",
"    </a>",
"    ], no studies have assessed whether treatment reduces mortality in the ESRD population. The treatment of sleep apnea utilizes the same measures that have been shown to be effective in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to such measures, sleep apnea may be improved by changing the mode of renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20,82-84\">",
"     20,82-84",
"    </a>",
"    ]. Although sleep apnea is not corrected by conventional hemodialysis or peritoneal dialysis, nocturnal hemodialysis, which enables patients to receive hemodialysis at home during sleep, may improve sleep apnea. In one study, among seven subjects changing from conventional three times weekly hemodialysis to nocturnal hemodialysis was associated with a reduction in the AHI (approximately 46 to 9",
"    <span class=\"nowrap\">",
"     /hour,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ]. However, as noted previously, although nocturnal hemodialysis may reduce sleep apnea, it has the potential to cause sleep disruption for other reasons. (See",
"    <a class=\"local\" href=\"#H26619147\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients treated with nocturnal cycler-assisted peritoneal dialysis have also been shown to have decreased prevalence and severity of sleep apnea compared with those on CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/83\">",
"     83",
"    </a>",
"    ]. The improvement in sleep apnea was attributed to more effective fluid removal and its impact on the upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether transplantation improves sleep apnea. Case reports have suggested decreased sleep apnea following successful kidney transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. However results from case series have been mixed, with some indicating that sleep apnea improves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/89\">",
"     89",
"    </a>",
"    ] and others indicating that sleep apnea resolves in only a minority of patients following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/70\">",
"     70",
"    </a>",
"    ]. The persistence of sleep apnea following kidney transplantation may be related to nonrenal factors such as weight gain and a medication effect on the upper airway [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/90\">",
"     90",
"    </a>",
"    ]. In the transplant population, sleep apnea has also been associated with graft failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619203\">",
"    <span class=\"h1\">",
"     RESTLESS LEGS SYNDROME AND PERIODIC LIMB MOVEMENT DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS) refers to complaints of an unpleasant sensation in the legs (and occasionally in the arms) accompanied by an urge to move them, typically in the evening or early part of the night, that is worse during periods of inactivity and transiently relieved by movement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37,91\">",
"     37,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The restlessness experienced by patients with RLS may be problematic both during the daytime, especially during inactivity, and at nighttime when patients report difficulty initiating and maintaining sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/92\">",
"     92",
"    </a>",
"    ]. Periodic limb movement (PLM) disorder refers to involuntary jerking movement of the legs (and occasionally the arms) during sleep that may be disruptive to the patients or bed-partner [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37\">",
"     37",
"    </a>",
"    ]. RLS is almost always associated with PLM disorder but PLM can occur in the absence of RLS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619210\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon limited data, the reported prevalence of RLS among hemodialysis patients ranges from 14 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/4,7,92,93\">",
"     4,7,92,93",
"    </a>",
"    ] compared with a prevalence of 5 to 15 percent in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The variability in the reported prevalence of RLS may be due to the heterogeneity of the patient populations studied and differences in the criteria used to diagnose RLS.",
"   </p>",
"   <p>",
"    The prevalence of PLM among ESRD patients treated with conventional hemodialysis or CAPD, is greater than 50 percent, which is higher than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/4,8,20,30,31\">",
"     4,8,20,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"     \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619217\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"    </strong>",
"    pathogenesis of RLS and PLM in patients with ESRD is not understood. Factors that have been associated with these sleep disorders include anemia, iron deficiency, elevated serum calcium and peripheral and central nervous system abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37,93,94\">",
"     37,93,94",
"    </a>",
"    ]. In addition, alterations of central nervous system dopamine and opioid activity may contribute.",
"   </p>",
"   <p>",
"    Medications including tricyclic anti-depressants, serotonin re-uptake inhibitors, dopamine antagonists may exacerbate symptoms, as may excessive caffeine, alcohol and nicotine. Iron deficiency may contribute both by causing anemia and by altering central nervous system dopamine metabolism.",
"   </p>",
"   <p>",
"    Peripheral neuropathy, secondary to uremia or the underlying cause of ESRD (such as diabetes) may also predispose patients to develop RLS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PLM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619224\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, patients with restless legs syndrome (RLS) complain of an unpleasant sensation in the legs (and occasionally in the arms) accompanied by an urge to move them, typically in the evening or early part of the night, that is worse during periods of inactivity and transiently relieved by movement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37,91\">",
"     37,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with periodic limb movement (PLM) disorder have involuntary jerking movement of the legs (and occasionally the arms) during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients may report nocturnal awakenings associated with legs movements or, more commonly, rely on their bed partner to report them. Although both syndromes may present in the general population, RLS appears to progress more rapidly, is more severe and is less responsive to dopaminergic medications among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/95\">",
"     95",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619231\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;RLS is associated with difficulty initiating sleep, poor sleep quality and impaired health related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/7,21,92,96\">",
"     7,21,92,96",
"    </a>",
"    ]. Furthermore, RLS has been associated with depression in a cohort of patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/97\">",
"     97",
"    </a>",
"    ]. RLS and PLM may also be associated with increased mortality among ESRD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/57,92,96,98,99\">",
"     57,92,96,98,99",
"    </a>",
"    ]. Although the mechanism underlying the increased mortality is not known, potential explanations include poor compliance with therapy, depression, and the psychological and hemodynamic consequences of recurrent sleep disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/100-102\">",
"     100-102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619238\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of RLS is the same among ESRD patients as in the general population and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619245\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of restless leg syndrome is generally the same among ESRD patients as in the general population and is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of the modality of renal replacement therapy has been evaluated in a few studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20,103-107\">",
"     20,103-107",
"    </a>",
"    ]. One study reported that nocturnal hemodialysis does not correct PLM [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"     20",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    A subsequent study suggested that short daily hemodialysis reduces the prevalence and severity of RLS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/103\">",
"     103",
"    </a>",
"    ]. Kidney transplantation has been associated with an improvement in both RLS and PLM in several small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/16/2314/abstract/104-107\">",
"     104-107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26619252\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep disorders are common in patients with end-stage renal disease (ESRD) and tend to be under recognized by renal healthcare providers. Sleep disorders include insomnia, excessive sleepiness, sleep apnea, and restless legs syndrome. (See",
"      <a class=\"local\" href=\"#H26619091\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insomnia is a significant source of stress and has been associated with shorter survival among ESRD patients. Causes of insomnia include restless leg syndrome (RLS) and periodic limb movements (PLM), sleep apnea, metabolic factors, bone pain and pruritus, anxiety and depression, circadian rhythm disorders, medications and poor sleep hygiene, including frequent napping during daytime dialysis. Patients complain of difficulty initiating and maintaining sleep and early morning awakening. (See",
"      <a class=\"local\" href=\"#H271949745\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26619126\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among ESRD patients, the treatment of insomnia is directed at optimizing renal replacement therapy as well as utilizing non-pharmacologic and pharmacologic interventions which are employed for the treatment of insomnia in the general population. (See",
"      <a class=\"local\" href=\"#H26619147\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"       \"Treatment of insomnia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excessive sleepiness is defined as the inability to stay awake or alert during the major waking episodes of the day, resulting in unintended lapses into drowsiness or sleep. Subjective daytime sleepiness has been associated with a higher BUN, a higher frequency of periodic limb movement disorders (PLM) and with sleep apnea. (See",
"      <a class=\"local\" href=\"#H26619154\">",
"       'Excessive sleepiness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep apnea among ESRD patients is due both to destabilization of central ventilatory control and upper airway occlusion. Volume overload, neuropathy or myopathy associated with chronic uremia or the underlying cause of ESRD may contribute. (See",
"      <a class=\"local\" href=\"#H258227658\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ESRD patients may not have the typical manifestations of sleep apnea and objective monitoring may be required to exclude the diagnosis. The evaluation of patients with possible sleep apnea is the same among ESRD patients as in the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The decision to treat sleep apnea for the reduction of cardiovascular risk should be individualized for each patient. In general, the treatment of sleep apnea is the same among ESRD patients as in the general population. Among patients on conventional three times weekly hemodialysis, sleep apnea may be improved by switching to nocturnal hemodialysis, however nocturnal hemodialysis has the potential to cause sleep disruption for other reasons. Among patients on continuous ambulatory peritoneal dialysis (CAPD), switching to nocturnal peritoneal dialysis may improve sleep apnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"       \"Central sleep apnea: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restless legs syndrome (RLS) refers to complaints of an unpleasant sensation in the legs (and occasionally in the arms) accompanied by an urge to move them, typically in the evening or early part of the night, that is worse during periods of inactivity and transiently relieved by movement. Factors that exacerbate, if not cause, these sleep disorders among ESRD patients include anemia, iron deficiency, elevated serum calcium and peripheral and central nervous system abnormalities. RLS is associated with difficulty initiating sleep, poor sleep quality and impaired health related quality of life and with depression. (See",
"      <a class=\"local\" href=\"#H26619203\">",
"       'Restless legs syndrome and periodic limb movement disorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/1\">",
"      Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/2\">",
"      Weisbord SD, Fried LF, Mor MK, et al. Renal provider recognition of symptoms in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2007; 2:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/3\">",
"      Sabbatini M, Minale B, Crispo A, et al. Insomnia in maintenance haemodialysis patients. Nephrol Dial Transplant 2002; 17:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/4\">",
"      Walker S, Fine A, Kryger MH. Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995; 26:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/5\">",
"      Iliescu EA, Coo H, McMurray MH, et al. Quality of sleep and health-related quality of life in haemodialysis patients. Nephrol Dial Transplant 2003; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/6\">",
"      Hsu CY, Lee CT, Lee YJ, et al. Better sleep quality and less daytime symptoms in patients on evening hemodialysis: a questionnaire-based study. Artif Organs 2008; 32:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/7\">",
"      Mucsi I, Molnar MZ, Ambrus C, et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant 2005; 20:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/8\">",
"      Hui DS, Wong TY, Ko FW, et al. Prevalence of sleep disturbances in chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 36:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/9\">",
"      Lui SL, Ng F, Lo WK. Factors associated with sleep disorders in Chinese patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2002; 22:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/10\">",
"      Yngman-Uhlin P, Ed&eacute;ll-Gustafsson U. Self-reported subjective sleep quality and fatigue in patients with peritoneal dialysis treatment at home. Int J Nurs Pract 2006; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/11\">",
"      Holley JL, Nespor S, Rault R. A comparison of reported sleep disorders in patients on chronic hemodialysis and continuous peritoneal dialysis. Am J Kidney Dis 1992; 19:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/12\">",
"      Eryavuz N, Yuksel S, Acarturk G, et al. Comparison of sleep quality between hemodialysis and peritoneal dialysis patients. Int Urol Nephrol 2008; 40:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/13\">",
"      De Vecchi A, Finazzi S, Padalino R, et al. Sleep disorders in peritoneal and haemodialysis patients as assessed by a self-administered questionnaire. Int J Artif Organs 2000; 23:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/14\">",
"      Unruh ML, Buysse DJ, Dew MA, et al. Sleep quality and its correlates in the first year of dialysis. Clin J Am Soc Nephrol 2006; 1:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/15\">",
"      Parfrey PS, Vavasour HM, Henry S, et al. Clinical features and severity of nonspecific symptoms in dialysis patients. Nephron 1988; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/16\">",
"      Elder SJ, Pisoni RL, Akizawa T, et al. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2008; 23:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/17\">",
"      Chiu YL, Chuang YF, Fang KC, et al. Higher systemic inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dial Transplant 2009; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/18\">",
"      Bornivelli C, Alivanis P, Giannikouris I, et al. Relation between insomnia mood disorders and clinical and biochemical parameters in patients undergoing chronic hemodialysis. J Nephrol 2008; 21 Suppl 13:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/19\">",
"      Novak M, Shapiro CM, Mendelssohn D, Mucsi I. Diagnosis and management of insomnia in dialysis patients. Semin Dial 2006; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/20\">",
"      Hanly PJ, Pierratos A. Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 2001; 344:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/21\">",
"      Loewen A, Siemens A, Hanly P. Sleep disruption in patients with sleep apnea and end-stage renal disease. J Clin Sleep Med 2009; 5:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/22\">",
"      Virga G, Stanic L, Mastrosimone S, et al. Hypercalcemia and insomnia in hemodialysis patients. Nephron 2000; 85:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/23\">",
"      Koch BC, Nagtegaal JE, Hagen EC, et al. Subjective sleep efficiency of hemodialysis patients. Clin Nephrol 2008; 70:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/24\">",
"      G&uuml;ney I, Biyik M, Yeksan M, et al. Sleep quality and depression in peritoneal dialysis patients. Ren Fail 2008; 30:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/25\">",
"      Yang JY, Huang JW, Peng YS, et al. Quality of sleep and psychosocial factors for patients undergoing peritoneal dialysis. Perit Dial Int 2007; 27:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/26\">",
"      Pai MF, Hsu SP, Yang SY, et al. Sleep disturbance in chronic hemodialysis patients: the impact of depression and anemia. Ren Fail 2007; 29:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/27\">",
"      Sugimoto T, Nagake Y, Sugimoto S, et al. Plasma orexin concentrations in patients on hemodialysis. Nephron 2002; 90:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/28\">",
"      Barmar B, Dang Q, Isquith D, et al. Comparison of sleep/wake behavior in CKD stages 4 to 5 and hemodialysis populations using wrist actigraphy. Am J Kidney Dis 2009; 53:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/29\">",
"      Bastos JP, Sousa RB, Nepomuceno LA, et al. Sleep disturbances in patients on maintenance hemodialysis: role of dialysis shift. Rev Assoc Med Bras 2007; 53:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/30\">",
"      Hanly PJ, Gabor JY, Chan C, Pierratos A. Daytime sleepiness in patients with CRF: impact of nocturnal hemodialysis. Am J Kidney Dis 2003; 41:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/31\">",
"      Parker KP, Bliwise DL, Bailey JL, Rye DB. Daytime sleepiness in stable hemodialysis patients. Am J Kidney Dis 2003; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/32\">",
"      Unruh ML, Sanders MH, Redline S, et al. Subjective and objective sleep quality in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the sleep heart health study. Am J Kidney Dis 2008; 52:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/33\">",
"      Novak MJ, Sheth H, Bender FH, et al. Improvement in Pittsburgh Symptom Score index after initiation of peritoneal dialysis. Adv Perit Dial 2008; 24:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/34\">",
"      Bro S, Bjorner JB, Tofte-Jensen P, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/35\">",
"      Eryilmaz MM, Ozdemir C, Yurtman F, et al. Quality of sleep and quality of life in renal transplantation patients. Transplant Proc 2005; 37:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/36\">",
"      Novak M, Molnar MZ, Ambrus C, et al. Chronic insomnia in kidney transplant recipients. Am J Kidney Dis 2006; 47:655.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 2005; 2nd ed.: Diagnostic and coding manual:",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/38\">",
"      Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/39\">",
"      Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/40\">",
"      Stepanski E, Faber M, Zorick F, et al. Sleep disorders in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/41\">",
"      Parker KP, Bliwise DL, Rye DB, De A. Intradialytic subjective sleepiness and oral body temperature. Sleep 2000; 23:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/42\">",
"      Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22:667.",
"     </a>",
"    </li>",
"    <li>",
"     Heslegrave R, Thornley K, Ouwendyk M, Francoeur R et al. Impact of nocturnal hemodialysis on sleep and daytime cognitive functioning in patients with chronic renal failure. Sleep 1998; 21:51.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/44\">",
"      Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/45\">",
"      Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/46\">",
"      Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/47\">",
"      Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010; 182:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/48\">",
"      Mooe T, Franklin KA, Wiklund U, et al. Sleep-disordered breathing and myocardial ischemia in patients with coronary artery disease. Chest 2000; 117:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/49\">",
"      Lavie L. Obstructive sleep apnoea syndrome--an oxidative stress disorder. Sleep Med Rev 2003; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/50\">",
"      Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/51\">",
"      Lavie L. Sleep-disordered breathing and cerebrovascular disease: a mechanistic approach. Neurol Clin 2005; 23:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/52\">",
"      Zoccali C, Benedetto FA, Tripepi G, et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int 1998; 53:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/53\">",
"      Zoccali C, Mallamaci F, Tripepi G, Benedetto FA. Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. Nephrol Dial Transplant 2001; 16:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/54\">",
"      Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 2001; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/55\">",
"      Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/56\">",
"      Tang SC, Lam B, Yao TJ, et al. Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney Int 2010; 77:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/57\">",
"      Benz RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000; 35:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/58\">",
"      Kimmel PL, Miller G, Mendelson WB. Sleep apnea syndrome in chronic renal disease. Am J Med 1989; 86:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/59\">",
"      Wadhwa NK, Mendelson WB. A comparison of sleep-disordered respiration in ESRD patients receiving hemodialysis and peritoneal dialysis. Adv Perit Dial 1992; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/60\">",
"      Unruh ML, Sanders MH, Redline S, et al. Sleep apnea in patients on conventional thrice-weekly hemodialysis: comparison with matched controls from the Sleep Heart Health Study. J Am Soc Nephrol 2006; 17:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/61\">",
"      Mendelson WB, Wadhwa NK, Greenberg HE, et al. Effects of hemodialysis on sleep apnea syndrome in end-stage renal disease. Clin Nephrol 1990; 33:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/62\">",
"      Beecroft JM, Pierratos A, Hanly PJ. Clinical presentation of obstructive sleep apnea in patients with end-stage renal disease. J Clin Sleep Med 2009; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/63\">",
"      Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/64\">",
"      Patil SP, Schneider H, Schwartz AR, Smith PL. Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest 2007; 132:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/65\">",
"      de Oliveira Rodrigues CJ, Marson O, Tufic S, et al. Relationship among end-stage renal disease, hypertension, and sleep apnea in nondiabetic dialysis patients. Am J Hypertens 2005; 18:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/66\">",
"      Jung HH, Han H, Lee JH. Sleep apnea, coronary artery disease, and antioxidant status in hemodialysis patients. Am J Kidney Dis 2005; 45:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/67\">",
"      Tada T, Kusano KF, Ogawa A, et al. The predictors of central and obstructive sleep apnoea in haemodialysis patients. Nephrol Dial Transplant 2007; 22:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/68\">",
"      Elias RM, Castro MC, de Queiroz EL, et al. Obstructive sleep apnea in patients on conventional and short daily hemodialysis. Am J Nephrol 2009; 29:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/69\">",
"      Beecroft J, Duffin J, Pierratos A, et al. Enhanced chemo-responsiveness in patients with sleep apnoea and end-stage renal disease. Eur Respir J 2006; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/70\">",
"      Beecroft JM, Zaltzman J, Prasad R, et al. Impact of kidney transplantation on sleep apnoea in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/71\">",
"      Jean G, Piperno D, Fran&ccedil;ois B, Charra B. Sleep apnea incidence in maintenance hemodialysis patients: influence of dialysate buffer. Nephron 1995; 71:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/72\">",
"      Pressman MR, Benz RL, Schleifer CR, Peterson DD. Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 1993; 43:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/73\">",
"      White DP. Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 2005; 172:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/74\">",
"      Younes M, Ostrowski M, Thompson W, et al. Chemical control stability in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2001; 163:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/75\">",
"      Beecroft JM, Duffin J, Pierratos A, et al. Decreased chemosensitivity and improvement of sleep apnea by nocturnal hemodialysis. Sleep Med 2009; 10:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/76\">",
"      Anastassov GE, Trieger N. Edema in the upper airway in patients with obstructive sleep apnea syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/77\">",
"      Chiu KL, Ryan CM, Shiota S, et al. Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am J Respir Crit Care Med 2006; 174:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/78\">",
"      Shiota S, Ryan CM, Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007; 62:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/79\">",
"      Redolfi S, Yumino D, Ruttanaumpawan P, et al. Relationship between overnight rostral fluid shift and Obstructive Sleep Apnea in nonobese men. Am J Respir Crit Care Med 2009; 179:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/80\">",
"      Yumino D, Redolfi S, Ruttanaumpawan P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010; 121:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/81\">",
"      Beecroft JM, Hoffstein V, Pierratos A, et al. Pharyngeal narrowing in end-stage renal disease: implications for obstructive sleep apnoea. Eur Respir J 2007; 30:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/82\">",
"      Beecroft JM, Hoffstein V, Pierratos A, et al. Nocturnal haemodialysis increases pharyngeal size in patients with sleep apnoea and end-stage renal disease. Nephrol Dial Transplant 2008; 23:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/83\">",
"      Tang SC, Lam B, Ku PP, et al. Alleviation of sleep apnea in patients with chronic renal failure by nocturnal cycler-assisted peritoneal dialysis compared with conventional continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2006; 17:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/84\">",
"      Tang SC, Lam B, Lai AS, et al. Improvement in sleep apnea during nocturnal peritoneal dialysis is associated with reduced airway congestion and better uremic clearance. Clin J Am Soc Nephrol 2009; 4:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/85\">",
"      Kimoff RJ, Sforza E, Champagne V, et al. Upper airway sensation in snoring and obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/86\">",
"      Boyd JH, Petrof BJ, Hamid Q, et al. Upper airway muscle inflammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004; 170:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/87\">",
"      Auckley DH, Schmidt-Nowara W, Brown LK. Reversal of sleep apnea hypopnea syndrome in end-stage renal disease after kidney transplantation. Am J Kidney Dis 1999; 34:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/88\">",
"      Langevin B, Fouque D, L&eacute;ger P, Robert D. Sleep apnea syndrome and end-stage renal disease. Cure after renal transplantation. Chest 1993; 103:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/89\">",
"      Lee JJ, Kim GS, Kim JA, et al. Improvement of sleep-related breathing disorder in patients with end-stage renal disease after kidney transplantation. Clin Transplant 2011; 25:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/90\">",
"      Mallamaci F, Leonardis D, Tripepi R, et al. Sleep disordered breathing in renal transplant patients. Am J Transplant 2009; 9:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/91\">",
"      Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/92\">",
"      Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996; 28:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/93\">",
"      Kawauchi A, Inoue Y, Hashimoto T, et al. Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol 2006; 66:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/94\">",
"      Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/95\">",
"      Enomoto M, Inoue Y, Namba K, et al. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients. Mov Disord 2008; 23:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/96\">",
"      Unruh ML, Levey AS, D'Ambrosio C, et al. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004; 43:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/97\">",
"      Szentkiralyi A, Molnar MZ, Czira ME, et al. Association between restless legs syndrome and depression in patients with chronic kidney disease. J Psychosom Res 2009; 67:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/98\">",
"      Jung HH, Lee JH, Baek HJ, et al. Nocturnal hypoxemia and periodic limb movement predict mortality in patients on maintenance hemodialysis. Clin J Am Soc Nephrol 2010; 5:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/99\">",
"      Molnar MZ, Szentkiralyi A, Lindner A, et al. Restless legs syndrome and mortality in kidney transplant recipients. Am J Kidney Dis 2007; 50:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/100\">",
"      Ali NJ, Davies RJ, Fleetham JA, Stradling JR. Periodic movements of the legs during sleep associated with rises in systemic blood pressure. Sleep 1991; 14:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/101\">",
"      Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/102\">",
"      Walters AS, Rye DB. Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke. Sleep 2010; 33:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/103\">",
"      Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011; 6:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/104\">",
"      Beecroft JM, Zaltzman J, Prasad GV, et al. Improvement of periodic limb movements following kidney transplantation. Nephron Clin Pract 2008; 109:c133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/105\">",
"      Yasuda T, Nishimura A, Katsuki Y, Tsuji Y. Restless legs syndrome treated successfully by kidney transplantation--a case report. Clin Transpl 1986; :138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/106\">",
"      Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002; 17:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/16/2314/abstract/107\">",
"      Molnar MZ, Novak M, Ambrus C, et al. Restless Legs Syndrome in patients after renal transplantation. Am J Kidney Dis 2005; 45:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16197 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2314=[""].join("\n");
var outline_f2_16_2314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26619252\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26619091\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26619098\">",
"      INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H271949745\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619126\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619140\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619147\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26619154\">",
"      EXCESSIVE SLEEPINESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619168\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619175\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619189\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619196\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H258227629\">",
"      SLEEP APNEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258227644\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H258227651\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258227658\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258227665\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258227679\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H258227686\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26619203\">",
"      RESTLESS LEGS SYNDROME AND PERIODIC LIMB MOVEMENT DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619210\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619217\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619224\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619231\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619238\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26619245\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26619252\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/16197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/16197|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/57/18335\" title=\"figure 1\">",
"      Survival according to presence or absence of sleep ap PD pts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/2/20526\" title=\"figure 2\">",
"      Ventilatory sensitivity to hypercapnia in ESRD pts on HD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2600?source=related_link\">",
"      Approach to the patient with excessive daytime sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=related_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=related_link\">",
"      Performance and safety risks of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_16_2315="Autoimmune hepatitis variants";
var content_f2_16_2315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Autoimmune hepatitis overlap syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune hepatitis-primary",
"biliary cirrhosis overlap",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a. AMA-positive with histological evidence suggesting",
"autoimmune hepatitis but not primary biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b. ANA and/or SMA-positive with histologic changes",
"suggestive of primary biliary cirrhosis (autoimmune cholangitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune hepatitis-primary",
"sclerosing cholangitis overlap",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AMA: antimitochondrial antibodies; ANA: antinuclear antibodies; SMA: smooth muscle antibodies.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2315=[""].join("\n");
var outline_f2_16_2315=null;
var title_f2_16_2316="Primary prevention CHD elderly";
var content_f2_16_2316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic considerations for primary prevention of coronary heart disease in elderly patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Low-density lipoprotein cholesterol level mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk factors*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapeutic considerations&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        130 - 159 (3.36 - 4.11)",
"       </td>",
"       <td>",
"        0 - 1",
"       </td>",
"       <td>",
"        Life-habit changes indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;2",
"       </td>",
"       <td>",
"        Intensify life-habit changes; special considerations for drug therapy&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        160 - 189 (4.14 - 4.89)",
"       </td>",
"       <td>",
"        0 - 1",
"       </td>",
"       <td>",
"        Intensify life-habit changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;2",
"       </td>",
"       <td>",
"        Consider adding drug therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;190 (&ge;4.91)",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Consider adding drug therapy to life-habit changes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk factors include cigarette smoking, hypertension, low high-density lipoprotein cholesterol level, advancing age (&ge;45 years in men and &ge;55 years in women or postmenopausal), and diabetes mellitus.",
"     <br>",
"      &bull; Life-habit changes include Step I diet, weight control, and regular exercise. Intensify life-habit changes include Step II diet, medically supervised weight reduction, and exercise program.",
"      <br>",
"       &Delta; Some authorities consider cholesterol-lowering drug therapy if a patient has diabetes mellitus plus other risk factors. Drug therapy also may be appropriate if the patient is considered at very high risk from multiple risk factors or from subclinical atherosclerosis.",
"       <br>",
"        &plusmn; Indicates with or without risk factors.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Grundy, SM, Cleeman, JI, Rifkind, BM, Kuller, LH, for the Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159:1670.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2316=[""].join("\n");
var outline_f2_16_2316=null;
var title_f2_16_2317="Worrisome headache features in children";
var content_f2_16_2317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features that may indicate intracranial pathology in children with headache",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Headache characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache awakens the child or occurs upon waking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sudden severe headache (\"thunderclap\" headache, \"worst headache of my life\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Associated neurologic signs and symptoms (eg, persistent nausea/vomiting, altered mental status, ataxia, etc)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache worsened in recumbent position or by cough, micturition, or defecation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of aura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic progressive headache pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Change in quality, severity, frequency, or pattern of headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occipital headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent localized headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of response to medical therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache duration of less than six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Examination findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal neurologic examination (eg, ataxia, weakness, diplopia, abnormal eye movements)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema or retinal hemorrhages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth abnormalities (increased head circumference, short stature or deceleration of linear growth, abnormal pubertal progression, obesity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuchal rigidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial bruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions that suggest a neurocutaneous syndrome (neurofibromatosis, tuberous sclerosis complex)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk factor for intracranial pathology (eg, sickle cell disease, immune deficiency, malignancy or history of malignancy, coagulopathy, cardiac disease with right-to-left intracardiac shunt, head trauma, neurofibromatosis type 1, tuberous sclerosis complex)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age &lt;3 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of family history of migraine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 59:490.",
"       </li>",
"       <li>",
"        Newton RW. Childhood headache. Arch Dis Child Educ Pract Ed 2008; 93:105.",
"       </li>",
"       <li>",
"        Prince JS, Gunderman R, Coley BD, et al. Expert Panel on Pediatric Imaging. ACR Appropriateness Criteria. Headache - child. American College of Radiology, Reston, VA, 2008. file://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonPediatricImaging/HeadacheChildDoc3.aspx (Accessed on March 17, 2011).",
"       </li>",
"       <li>",
"        Strasburger VC, Brown RT, Braverman PK, et al. Headache. In: Adolescent Medicine A Handbook for Primary Care, Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.25.",
"       </li>",
"       <li>",
"        Wilne S, Koller K, Collier J, et al. The diagnosis of brain tumours in children: a guideline to assist healthcare professionals in the assessment of children who may have a brain tumour. Arch Dis Child 2010; 95:534.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2317=[""].join("\n");
var outline_f2_16_2317=null;
var title_f2_16_2318="Retinopathy onset in NIDDM";
var content_f2_16_2318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Onset of retinopathy precedes diagnosis of type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 214px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of retinopathy in relation to years after onset of diabetes among patients in southern Wisconsin (blue circles) and rural western Australia (red squares). At diagnosis (year zero), retinopathy was already present in 10 to 20 percent of patients. The lines extrapolate back to an estimated onset of retinopathy four to seven years before the clinical diagnosis was made.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15:815.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2318=[""].join("\n");
var outline_f2_16_2318=null;
var title_f2_16_2319="Nondisplaced radial head fracture";
var content_f2_16_2319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced fracture of the radial head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 224px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These radiographs show a minimally displaced radial head fracture (Mason Type I).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Slabaugh, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_16_2319=[""].join("\n");
var outline_f2_16_2319=null;
